WO2007109845A1 - Prophylaxie ou traitement du diabète - Google Patents
Prophylaxie ou traitement du diabète Download PDFInfo
- Publication number
- WO2007109845A1 WO2007109845A1 PCT/AU2007/000381 AU2007000381W WO2007109845A1 WO 2007109845 A1 WO2007109845 A1 WO 2007109845A1 AU 2007000381 W AU2007000381 W AU 2007000381W WO 2007109845 A1 WO2007109845 A1 WO 2007109845A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- independently selected
- ligand
- group
- alkynyl
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 71
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 61
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 22
- 229910052751 metal Inorganic materials 0.000 claims abstract description 115
- 239000002184 metal Substances 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 102
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 94
- 150000007942 carboxylates Chemical class 0.000 claims abstract description 83
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 9
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indomethacin Natural products CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 207
- 239000003446 ligand Substances 0.000 claims description 203
- -1 2,6-dichlorophenyl Chemical group 0.000 claims description 112
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 103
- 229960000905 indomethacin Drugs 0.000 claims description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 89
- 229910021645 metal ion Inorganic materials 0.000 claims description 76
- 125000003342 alkenyl group Chemical group 0.000 claims description 72
- 239000010949 copper Substances 0.000 claims description 71
- 125000000304 alkynyl group Chemical group 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 150000001408 amides Chemical class 0.000 claims description 66
- 125000005843 halogen group Chemical group 0.000 claims description 60
- 229910001868 water Inorganic materials 0.000 claims description 60
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 239000011651 chromium Substances 0.000 claims description 47
- 150000004696 coordination complex Chemical class 0.000 claims description 45
- 239000002253 acid Substances 0.000 claims description 44
- 150000002148 esters Chemical class 0.000 claims description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 40
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 39
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 229910052802 copper Inorganic materials 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 27
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 25
- 229910052720 vanadium Inorganic materials 0.000 claims description 25
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 25
- 239000011701 zinc Substances 0.000 claims description 25
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 21
- 235000000346 sugar Nutrition 0.000 claims description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 17
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 229960004752 ketorolac Drugs 0.000 claims description 14
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 14
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 12
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052725 zinc Inorganic materials 0.000 claims description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229910052707 ruthenium Inorganic materials 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 229960004892 acemetacin Drugs 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 8
- 229960001680 ibuprofen Drugs 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 125000005493 quinolyl group Chemical group 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- CMWTZPSULFXXJA-UHFFFAOYSA-N 2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
- 229910052804 chromium Inorganic materials 0.000 claims description 7
- 229910052750 molybdenum Inorganic materials 0.000 claims description 7
- 239000011733 molybdenum Substances 0.000 claims description 7
- 229960003424 phenylacetic acid Drugs 0.000 claims description 7
- 229910052721 tungsten Inorganic materials 0.000 claims description 7
- 239000010937 tungsten Substances 0.000 claims description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 229910017052 cobalt Inorganic materials 0.000 claims description 6
- 239000010941 cobalt Substances 0.000 claims description 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 6
- 208000004104 gestational diabetes Diseases 0.000 claims description 6
- 229960002009 naproxen Drugs 0.000 claims description 6
- 229910052759 nickel Inorganic materials 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 5
- 229960001259 diclofenac Drugs 0.000 claims description 5
- 229960003422 indobufen Drugs 0.000 claims description 5
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 5
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229960004492 suprofen Drugs 0.000 claims description 5
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 4
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 4
- 208000035180 MODY Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 4
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- 229960004369 flufenamic acid Drugs 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 150000003873 salicylate salts Chemical class 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 206010071200 Carbohydrate intolerance Diseases 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims 4
- 239000003617 indole-3-acetic acid Substances 0.000 claims 2
- RKRXTVLCZDPERO-UHFFFAOYSA-N 2-methyl-6-nitro-1h-benzimidazole Chemical group C1=C([N+]([O-])=O)C=C2NC(C)=NC2=C1 RKRXTVLCZDPERO-UHFFFAOYSA-N 0.000 claims 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 91
- 241000700159 Rattus Species 0.000 description 78
- 239000000243 solution Substances 0.000 description 70
- 239000007787 solid Substances 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 38
- 230000002496 gastric effect Effects 0.000 description 38
- 125000001424 substituent group Chemical group 0.000 description 30
- 239000002904 solvent Substances 0.000 description 29
- 238000003756 stirring Methods 0.000 description 29
- 239000003814 drug Substances 0.000 description 27
- 150000001412 amines Chemical class 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 206010061218 Inflammation Diseases 0.000 description 19
- 230000004054 inflammatory process Effects 0.000 description 19
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
- 208000025865 Ulcer Diseases 0.000 description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 17
- 238000009472 formulation Methods 0.000 description 17
- 230000036269 ulceration Effects 0.000 description 17
- 210000002700 urine Anatomy 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 16
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 15
- 239000013078 crystal Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 14
- 230000001988 toxicity Effects 0.000 description 14
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 13
- 231100000331 toxic Toxicity 0.000 description 13
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000011572 manganese Substances 0.000 description 12
- 230000035699 permeability Effects 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 230000002526 effect on cardiovascular system Effects 0.000 description 11
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- 230000002411 adverse Effects 0.000 description 10
- 229940124599 anti-inflammatory drug Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 210000002683 foot Anatomy 0.000 description 10
- MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 239000002260 anti-inflammatory agent Substances 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical compound [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 231100000417 nephrotoxicity Toxicity 0.000 description 9
- 229960000273 oxametacin Drugs 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000004435 EPR spectroscopy Methods 0.000 description 8
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 239000003472 antidiabetic agent Substances 0.000 description 8
- 229910001431 copper ion Inorganic materials 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 238000010254 subcutaneous injection Methods 0.000 description 8
- 239000007929 subcutaneous injection Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 229940127003 anti-diabetic drug Drugs 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 6
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000014702 Haptoglobin Human genes 0.000 description 6
- 108050005077 Haptoglobin Proteins 0.000 description 6
- 206010022714 Intestinal ulcer Diseases 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000000129 anionic group Chemical group 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000010255 intramuscular injection Methods 0.000 description 6
- 239000007927 intramuscular injection Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 230000001562 ulcerogenic effect Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 229910001429 cobalt ion Inorganic materials 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 5
- 229910001453 nickel ion Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- AJRNYCDWNITGHF-UHFFFAOYSA-N oxametacin Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 description 5
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical group [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 150000003511 tertiary amides Chemical class 0.000 description 5
- 150000003751 zinc Chemical class 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 4
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 229910001430 chromium ion Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960005293 etodolac Drugs 0.000 description 4
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 238000000833 X-ray absorption fine structure spectroscopy Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 150000001879 copper Chemical class 0.000 description 3
- 150000004699 copper complex Chemical class 0.000 description 3
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010537 deprotonation reaction Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052733 gallium Inorganic materials 0.000 description 3
- 210000003736 gastrointestinal content Anatomy 0.000 description 3
- 230000010030 glucose lowering effect Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002608 insulinlike Effects 0.000 description 3
- 230000003870 intestinal permeability Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 229910001428 transition metal ion Inorganic materials 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000036325 urinary excretion Effects 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 2
- GTRGFUCVDQMYKO-UHFFFAOYSA-N 2-hydroxyethyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCO GTRGFUCVDQMYKO-UHFFFAOYSA-N 0.000 description 2
- XUOLEICXAPEOSI-UHFFFAOYSA-L 2-methyl-4-oxopyran-3-olate;oxovanadium(2+) Chemical compound [V+2]=O.CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] XUOLEICXAPEOSI-UHFFFAOYSA-L 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 125000006519 CCH3 Chemical group 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000878128 Malleus Species 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 201000002758 colorectal adenoma Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 108010009297 diglycyl-histidine Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 208000037902 enteropathy Diseases 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960002679 fentiazac Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000002331 malleus Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960000916 niflumic acid Drugs 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229960004662 parecoxib Drugs 0.000 description 2
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005137 succinic acid Drugs 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960003755 suxibuzone Drugs 0.000 description 2
- ONWXNHPOAGOMTG-UHFFFAOYSA-N suxibuzone Chemical compound O=C1C(CCCC)(COC(=O)CCC(O)=O)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 ONWXNHPOAGOMTG-UHFFFAOYSA-N 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000007944 thiolates Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 125000002827 triflate group Chemical class FC(S(=O)(=O)O*)(F)F 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229960002004 valdecoxib Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- 150000003682 vanadium compounds Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical group C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- CTXGTHVAWRBISV-UHFFFAOYSA-N 2-hydroxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCO CTXGTHVAWRBISV-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000008570 Digitaria exilis Species 0.000 description 1
- 235000005459 Digitaria exilis Nutrition 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical class OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 229920002507 Poloxamer 124 Polymers 0.000 description 1
- 229920002516 Poloxamer 331 Polymers 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical class OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002056 X-ray absorption spectroscopy Methods 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010017893 alanyl-alanyl-alanine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000307 algesic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 208000025870 aspirin resistance Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 229940052223 basic fuchsin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000001891 corneal deposit Diseases 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002336 glycosamine derivatives Chemical class 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- UHOKSCJSTAHBSO-UHFFFAOYSA-N indanthrone blue Chemical compound C1=CC=C2C(=O)C3=CC=C4NC5=C6C(=O)C7=CC=CC=C7C(=O)C6=CC=C5NC4=C3C(=O)C2=C1 UHOKSCJSTAHBSO-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AKFJWRDCWYYTIG-ZDUSSCGKSA-N naproxcinod Chemical compound C1=C([C@H](C)C(=O)OCCCCO[N+]([O-])=O)C=CC2=CC(OC)=CC=C21 AKFJWRDCWYYTIG-ZDUSSCGKSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical group OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100001090 no gastrointestinal toxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940094335 peg-200 dilaurate Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229940093448 poloxamer 124 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008664 renal activity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229910001456 vanadium ion Inorganic materials 0.000 description 1
- YGYBXHQARYQUAY-UHFFFAOYSA-L vanadyl sulfate pentahydrate Chemical compound O.O.O.O.O.[V+2]=O.[O-]S([O-])(=O)=O YGYBXHQARYQUAY-UHFFFAOYSA-L 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention relates to the prophylaxis or treatment of diabetes.
- the present invention relates to a method for the prophylaxis or treatment of diabetes comprising the administration of a metal complex having antiinflammatory activity.
- Non-steroidal anti-ii ⁇ flammatory drugs are used in the treatment of a variety of inflammatory conditions.
- NSAIDs are, for example, used to treat inflammatory conditions such as rheumatoid arthritis, osteoarthritis, acute musculoskeletal disorders (such as tendonitis, sprains and strains), lower back pain (commonly referred to as lumbago), and inflammation, pain and edema following surgical or non-surgical procedures.
- GI adverse gastrointestinal
- Indomethacin is a NSAID effective in treating inflammatory conditions in both humans and animals.
- the structure of indomethacin is as follows:
- indomethacin can cause ulcerations in the oesophagus, stomach, duodenum and intestines. In dogs, oral administration of indomethacin causes fatal gastrointestinal haemorrhaging.
- Other effects associated with oral administration of indomethacin include: (a) inhibition of platelet aggregation, (b) adverse cardiovascular effects (fluid retention and peripheral oedema), (c) ocular effects (corneal deposits and retinal disturbances), (d) central nervous system effects (headaches and dizziness), (e) masking of infections due to antipyretic properties, and (f) renal effects (as with other NSAE)S, there have been reports of acute interstitial nephritis wifh hematuria, proteinuria and, occasionally, nephrotic syndrome in patients receiving long-term administration of indomethacin).
- indomethacin e.g. as a suppository or by topical application can have adverse effects.
- Anti-inflammatory activity of Indomethacin following topical application Amico-Roxas, M., Mater, M., Caruso, A., Puglisi, G., Bemadini, R., Rinaldo, G., European Review for Medical & Pharmacological Sciences, 1982, IV,
- dinuclear metal complexes of indomethacin i.e. complexes containing two metal coordination centres
- DMF N, ⁇ T-dimethylformamide
- the NSATD aspirin acetylsalicy ⁇ ic acid
- acetylsalicy ⁇ ic acid is widely used in low dosages to prevent cardiovascular events and is generally prescribed as a standard treatment for prophylaxis of cardiac disease in high-risk patients.
- the effect of aspirin is not consistent with a significant proportion of the population (up to 45%) being aspirin resistant ("Aspirin resistance: Definitions, mechanisms, prevalence, and clinical significance", Macchi, L.. Scrrel, N., Christiaens, L., Curr. Pharm. Des., 2006, 12, 25J- 258).
- COX-2 inhibitors such as rofecoxib, celccoxib, valecoxib and parecoxib may be associated with an increased ri$k of thrombotic events ("Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention", Scott, D.
- NSAIDs are another class of drug that have been shown to have beneficial effects on the prevention and treatment of diabetes, including hydroxamic acid derivatives of NSAIDs.
- hydroxamic acid derivatives of NSAIDs Wang, T.; Lai, C-S. United States Patent Publication No. 20040077691 (CIP of US 6,620,813) (2004).
- hydroxamic acid complexes of vanadium have previously been shown to exhibit glucose lowering effects when delivered by intraperitoneal injection, but only show similar glucose lowering effects to the insulin mimetic complexes discussed above when administered at a similar concentration.
- the present invention steins from the recognition that at least some metals have application in the treatment of diabetes and the condition commonly if not invariably has associated inflammatory components), and that metal complexes having antiinflammatory activity may be employed to therapeutically target one of both of these treatment pathways. While both metals and NSAIDs are known to separately exert anti-diabetic effects, the present i ⁇ ventots have surprisingly found that in at least some embodiments, metal complexes of NSAIDs can have an in-vivo glucose lowering effect that is comparable to the best vanadium drugs previously used for the treatment of diabetes but at significantly lower dose of up to orders of magnitude difference.
- a method for the prophylaxis or treatment of a diabetes in a mammalian subject comprising treating the subject with a therapeutically effective amount of a complex of a metal and a carboxylate, or derivative of a carboxylate, having anti-inflammatory activity, wherein the carboxylate or derivative is other than salicylate or a derivative of salicylate,
- the carboxylate or the derivative of the carboxylate having anti-inflammatory activity will generally have such activity when administered to a human or animal.
- the derivative of the carboxylate can be hydrolysed in vivo, and the hydrolysed compound may have anti-inflammatory activity
- the derivative of the carboxylate can be selected from the group consisting of ahydroxamate, hydroximate, amide or ester. These derivatives have functional groups that bind to one or more tnetal(s) as a monodentate ligand, a chelate and/or a bridging ligand.
- a method for the prophylaxis or treatment of diabetes in a mammalian subject comprising treating the subject with a therapeutically effective amount of a complex of a metal and a carboxylate, or a hydroxamate, hydroxiraate, amide or ester, having anti- inflammatory activity.
- the carboxylate having anti-inflammatory activity can be any deproto ⁇ ated carboxylic acid compound having anti-inflammatory activity.
- the carboxylate having anti-inflammatory activity may, for example, be the dcprotonated anionic form of any one of the following carboxyiic acids NSAIDs: Suprofen ((+)- ⁇ -methyI-4-(2 ⁇ thienylcarbonyl) ⁇ henylacetic acid (“SupH”));
- ToIH Tolmetin (1-methyl-5-(p-toluoyl)-lH-pyrrole-2-acetic acicl
- Naproxen ⁇ -methoxy- ⁇ -methyl- ⁇ -naphthaleneacetic acid
- IbuH Ibuprofen
- Fhrfenamic Acid ( ⁇ trifluoromethylphenyljanthrati ⁇ ic acid (“FlufenH”)
- Indomethacin (l-(4-chlorobenzoyl)-5-methoxy-2-methyl-lH-indole-3-acctic acid (“IndoH”)); Acemetacin (l-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid carboxymethyl ester (“ACMH”))
- Ketorolac ( ⁇ )-5-benzoyl-2,3-dihydro-lH-pyrro]izine-l-carboxylic acid
- Indobufen in addition to its anti-inflammatory effects, i$ used to prevent thrombosis in much the same way as aspirin, but suffers from the same problems as the other anti-inflammatory drugs in terms of GI toxicity at therapeutic doses, although the effects are not a$ severe as aspirin.
- the inclusion of the "H" at the end of an abbreviation for a carboxylate e.g., any one of the carboxylic acids listed above
- a hydroxaraate, S hydroximate, or amide is used to refer to the uncharged form of the carboxylate or amide or the parent hydroxamic acid or its monodeproto ⁇ ated hydroxamate form of the doubly deprotonated hydroximate. Accordingly, the abbreviation without the "H” is used to refer to the deprotonated anionic form.
- IndoH refers to the uncharged form of indomethacin
- Indo is used to refer to the deprotonated o anionic form of indomethacin
- ACMH refers to the uncharged form of acemetacin
- ACM refers to the deprotonated anionic form.
- the carboxylate, or hydroxamate, hydroxi ⁇ iate, hydrazide, ester or amide derivative having anti-inflammatory activity can be any non-steroidal anti-inflamniatory drug (NSAID).
- the NSAID can be indomethacin (IndoH), or an ester 5 derivative of indomethacin, such as acemetacin, ibuprofen, indobufen, diclofenac, vaproxen, or ketorolac, or a hydroxamate, hydroximate, or amide derivative of ⁇ idomethacin or acemetacin or other NSAED.
- hydroxamate or hydroximate are to be taken to mean the deprotonated and doubly deprotonated forms of the ligands.
- NSAIDs that can be utilized in the metal complexes (as can their derivatives) as 0 described herein include;
- Carprofen (6-chloro-a-methyl-9H-carbazole-2-acetic acid);
- Etodolac (1 ,8-diethyl-1 5 3,4,9-tetrahydro-pyrano[3,4-b]indole-l-acetio a ⁇ id);
- Flurbiprofen (2-fluoro-a-methyl-[l,r-biphcnyl]-4-acetic acid); 5 Ketoprofen (3-benzoyl-a-methylbcnzcneacctic acid);
- Oxaprozin (4,5-diphenyl-2-oxazolepropanoic acid);
- Pranoproftn (a-methyl-5H-[l]benzo ⁇ yrano[2,3-b]pyridine-7-acetic acid);
- Sulindac (I Z)-5-fluoro-2-methyl-l -[[4-(methylsulfinyl)phenyl]methy]ene]- lH-indene-3 -acetic acid); and 0 Suxibuzone (butanedioic acid, l-[(4-butyl-3,5-dioxo-l,2-diphe ⁇ iyl-4- pyrazolidinyl) ⁇ iethyl] ester).
- Acemetacin I -(4-chlorobenzoyl)-5-methoxy-2-methyIindole-3 -acetic acid carboxymethyl ester, is a glycolic acid ester of indometkacin. The structure of acemetacin is shown below as is the structure for ketorolac.
- the metal complex used in a method embodied by the invention can be any complex comprising at least one metal ion and at least one carboxylate, or hydroxamate, hydroxirnate, hydrazide, ester or aaiide derivative having anti-inflammatory activity.
- the carboxylate or hydroximate, hydroxamate, ester or amide derivative can be coordinated with the metal ion via the carboxylate, hydroximate, hydroxamate, amide and/or other groups attached to the amide or ester linkages, such as sugars, amino acids, peptides, chelates containing heterocycles, and other chelating ligands.
- the metal complex may be a mononuclear, dinuclear, or trinuclear metal complex, or a metal complex having higher nuclearity, or an oligomeric or polymeric complex containing one or more metal centres and one or more carboxylates, or derivatives of a carboxyl&te (eg,, hydroxamate, hydroximate, hydrazide, ester, and amide ligands) having anti-inflammatory activity.
- a carboxyl&te eg, hydroxamate, hydroximate, hydrazide, ester, and amide ligands
- the complex includes other ligands in addition to the carboxylate or carboxylate derivative(s) having anti-inflammatory activity.
- these other ligands can also have anti-inflammatory and/or anti-cancer activities.
- the complex is one of the following complexes (eg., see Copper Complexes of Non-steroidal Anti-inflammatory Drugs; An Opportunity yet to be Realized Weder, J. E.; Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Biffin, J. R.; Regtop, H. L.; Davies, N. M. Coord Chem. Rev, 2002, 232, 95-126).
- complexes eg., see Copper Complexes of Non-steroidal Anti-inflammatory Drugs; An Opportunity yet to be Realized Weder, J. E.; Dillon, C. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Biffin, J. R.; Regtop, H. L.; Davies, N. M. Coord Chem. Rev, 2002, 232, 95-126).
- Ibuprofen (+-)- ⁇ -methyl-4-(i$op ⁇ pylmethyl)benzeneacetic acid (IbuH); ⁇ ⁇ Metronidazole - 2-methyl-5-nitrobe ⁇ zimidaz ⁇ le s
- Flufenamic Acid (N-trifluoromethylphenyi)anthranilic acid (FlufenH);
- a Niflumic Acid 2-(3-t ⁇ fl.uoromethyl)phenylamino)-3-pyridineoarb ⁇ ylic acid
- Indotnethacin l-(4-chlorol>enzoyl)-S- ⁇ iethoxy-2-tnethyl-1H-indole-3-acetic acid (IndoH);
- J Diclofenac 2-[(2,6-dichlorophenyl)araino]phenylacetiQ acid (DicH); and M a i$ a metal ion and in at least some enbodhents, a transition metal ion,
- M a can, for example, be a copper ion.
- the complex can be any one of the complexes referred to in the table above in which the metal ion is a transition metal ion other than copper (eg icinc, nickel, ruthenium, iron, cobalt ions, and preferably zinc or ruthenium). See for instance, Copper and Zinc Complexes as Anti- Inflammatory Drugs. Dillon, C, T.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; Weder, J, E.; Zhou, Q.
- the complex is a mononuclear, dinuclear, trinuclear or poly ⁇ uclear complex of a metal (where each metal of the complex is independently selected) and a ligand of the formula L 2 :
- R' is H or halo (i.e. Cl, F, Br or I);
- R 2 is H; a Ci to Ce alkyl, an alkenyl or an alkynyl, where the Cj to C$ alkyl, alkenyl or alkynyl may be optionally substituted; or
- each R 2A is independently selected from the group consisting of H, Ci to Ct alkyi, alkenyl., alkynyl, aryl, cycloalkyl and arylalkyl, where tiie Ci to Cs alkyl, alkenyl, alkynyi, aryl, cycloalkyl or arylalkyl may be optionally substituted;
- R 3 is H or halo
- each R 5 is independently selected from the group consisting of halo, -CH 3 ,
- n 1 , 2, 3, 4 or 5.
- R 2 is a C 1 to Ce alkyl, an alkenyl or an alkynyl
- the Ci to C 6 alkyl, 0 alkenyl or alkynyl may be substituted with one or more substituents.
- the one or mote substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 2A is a Ci to C* alkyl, an alkenyl, an alkynyl, an aryl, a cycloalkyl or an arylalkyl
- the Ci to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl may be 5 substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 5 is -CH 3 , -OCH 3 , -SCH 3 Or-CH 2 CH 3
- the -CH 3 , -OCH 3 , -SCH 3 or - CH 2 CH 3 may be substituted with one or more substituents.
- the one or more O substituents may, for example, be independently selected from the group consisting of halo, -OH 5 -COOH and -NH 2 .
- the complex can be a complex of formula (I), (2) or (3):
- L 2 is a ligand as defined above: each L is independently selected and is amonodentate ligand; m is 1 or 2,' and 0 p is the charge of the complex;
- each M is independently selected and is a divalent or bivalent metal ion
- L 2 is a ligand as defined above:
- each L is independently selected and is a monodentate ligand; • m is 0, 1 or 2; and p is the charge of the complex;
- each M r is independently selected and is a trivale ⁇ t or tetravalent metal ion
- L 2 is a ligand as defined above: each L is independently selected and is a monodentate ligand; and 5 p is the charge of the complex.
- R 2 is a Ci to C 6 alkyl, an alkenyl or an alkynyl
- the C 1 to Cg alkyl, alkenyl or alky ⁇ yl may be substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH2.
- R 2A is a Ci to C 6 alkyl, an alkenyl, an alkynyl, an aryi, a cycloalkyl or an arylalkyl
- the Ci to Ce alkyl, alkenyl, alky ⁇ yl, aryl, cycloalkyl or arylalkyl may be substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 . 5
- R 5 is -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 , the
- -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 may be substituted with one or mote substituents.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 1 is typically H.
- 0 R 3 is typically H.
- R 2 is typically CH 3 .
- L 2 is ACM.
- M may be any divalent or trivalent metal ion, M is preferably copper ion, zinc ion, cobalt ion, nickel ion, chromium ion, molybdenum ion, tungsten ion or ruthenium ion. More preferably, M is a copper or zinc ion.
- M' may be any trivalent or tctravalent metal ion.
- M' is preferably iron ion, vanadium ion, manganese ion, chromium ion or ruthenium ion, and more preferably iron ion or ruthenium ion.
- the liga ⁇ d L may be any monodentate ligand.
- L may be a charged or uncharged ligand, L may for example be water, an alcohol, jV,N-dimethylformamide (DMF), iV-methylpyrrolidone, dimethylsulfoxide or N ⁇ -dimethylacetamide (DMA).
- DMF jV,N-dimethylformamide
- iV-methylpyrrolidone dimethylsulfoxide or N ⁇ -dimethylacetamide
- DMA N ⁇ -dimethylacetamide
- the complexes of formula (1), (2) or (3) may be dissolved in a solvent, or may be in the form of a solid Crystals of a complex of formula (1), (2) or (3) may include solvents of crystallisation. Crystals of a complex of formula (1 ), (2) or (3) may also include waters of crystallisation.
- the complex is a mononuclear complex of the following formula (4):
- M is a divalent or trivalent metal ion
- L 1 is a ligand of the formula
- R 1 is H or halo (i.e. Cl, F, Br or I);
- R 2 is H; a Ci to Q alkyl, an alkenyl or an alkynyl, where the C 1 to Ce alkyl, alkenyl or alkynyl may be optionally substituted; Of
- each R 2A is independently selected from the group consisting of H, Ci to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl and arylalkyl, where the Cj to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl may be optionally substituted;
- R 3 is H or halo;
- each R" 1 is independently selected from the group consisting of halo, -CHj, -CN, -OCH 3 , -SCH 3 and -CH 2 CH 3 , where the -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 may be optionally substituted.
- n is i, 2, 3, 4 or 5; each L is independently selected and is a monodentate ligand; m is 1 or 2; and p is the charge of the complex;
- the mononuclear complex of formula (4) is a complex of formula (4A):
- M is a divalent or divalent metal ion
- ⁇ 2 -L' is a bidentate ligand of the formula L 1 ;
- R 1 is H or halo (i.e. Cl, F, Br or I);
- R 2 is H; a C 1 to Cs alkyl, an alkenyl or an alkynyl, where the Ci to Cs alkyl, alkeityl or alkynyl may be optionally substituted; or
- each R 2A is independently selected from the group consisting of H, Ci to Cg alkyl, alkenyl, alkynyl, aryl, cycloalkyl and arylalkyl, where the Ci to Ce alkyl, 0 alketiyl, alkynyi, aryl, cycloalkyl or arylalkyl may be optionally substituted;
- R 3 is H or halo; each R 5 is independently selected from the group consisting of halo, -CH 3 , -CN 3 -OCH 3 , -SCH 3 and -CH 2 CH 3 , where the -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 may be optionally substituted; 5 n is 1, 2, 3, 4 or 5; each L is independently selected and is a monodentate ligand; and p is the charge of the complex.
- R 3 is a Ci to Ce alkyl, an alkenyl or an alkynyl
- the Ci to C(, alkyl, alkeny] or alkynyl may be substituted with one or more substituent$, O
- the one or more siibstLtuents may, for example, be independently selected from the group coti$i$ting of halo, -OH, -COOH and -NH 2 .
- R 2A is a Ci to Ce alkyl, an alkenyl, an alkynyl, an aryl, a cycloalkyl or an arylalkyl
- the Ci to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl may be substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 5 i$ -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 when R 5 i$ -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 , the - CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 may be substituted with one ot more substituents.
- the 5 one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 1 is typically H
- R 3 is typically H
- R 2 is typically CH 3 , 0
- T each R 5 is typically halo (i.e. F, Cl, Br or I) ? and n is typically I 1 2 or 3.
- L 1 may for example be Indo.
- M may be any divalent or trivalent metal ion.
- M is preferably copper ion, zinc ion, cobalt ion, nickel ion, chromium ion, molybdenum ion, 5 tungsten ion or ruthenium ion. More preferably, M is copper ion or zinc ion.
- the complex is a dinuclear complex of the formula (5);
- each M is independently selected and is a divalent or trivalent metal ion
- O ⁇ -L 1 is a ligand of the formula L 1 :
- R 1 is H or halo (i.e. Cl, F, Br or I); 5 R 2 is H; a Cj to Co alkyl, an alkenyl or an alkynyl, where the Ci to Cs alkyl, alkenyl or alkynyl may be optionally substituted; or wherein each R 2A is independently selected from the group consisting of H, Ci to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl and arylalkyl, where the Ci to Ce alkyl, alkenyl, aikynyl, aryl, cycloalkyl or arylalkyl maybe optionally substituted; 5 R 3 is H or halo; each R 5 is independently selected from the group consisting of halo, -CHj, -CN, -OCH 3 , -SCH 3 and -CH 2 CH 3 , where the -CH 3 , -OCH 3 , -SCH 3 Or-CH 2
- R 2 is a Ci to C ⁇ alkyl, an alkenyl or an alkynyl
- the Ci to Ce alkyl, alkenyl or alkynyl may be substituted with one or more sub$tituents.
- the one 5 or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 2A is a Ci to C 6 alkyl, an alkenyl, an alkynyl, an aryl, a Cycloalkyl or an arylalkyl
- the Ci to C 6 alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl may be substituted with one or more substituents.
- the one or more O substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 5 when R 5 is -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 , the -CH 3> -OCH 3 , -SCH 3 or -CHjCH 3 may be substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group 5 consisting of halo, -OH, -COOH and -NH 2 .
- R 1 is typically H.
- R 3 is typically H.
- R s is typically CH 3 .
- L 1 may for example be Indo.
- M is any divalent or trivalent metal ion. M is typically selected from copper ion, zinc ion, cobalt ion, nickel ion, chromium ion, molybdenum ion, tungsten ion and ruthenium ion. Preferably, M is copper ion.
- the ligand L maybe any monodentate ligand, L may, for example, be water (OH 2 X an alcohol, dimethylsulfoxide (DMSO) 4 tetrahydrofuran (THF), or L may be a ligand containing a tertiary amide or cyclic tertiary amide.
- DMSO dimethylsulfoxide
- THF tetrahydrofuran
- the complex is a trinuclear complex of the following formula (6):
- each M' is independently selected and is a trivalent or tetravalent metal ion; and ⁇ -L 1 , L and p are as defined above for formula (5).
- the complex is a trinuclear complex of the following formula (7):
- M is a divalent metal ion
- L 3 is a carboxylate having anti-inflammatory activity
- L 4 is an optionally substituted heterocyclic base comprising one or two heterocyclic rings independently having 5 or 6 ring members and I to 3 heteroatoms independently selected from N, O and S; wherein each L 3 is independently selected; and each L 4 i$ independently selected.
- L 3 can be a monodentate, bidentate or bridging ligand of formula L 1 or L 2 a$ follows;
- R 1 i$ H or halo i.e. Cl, F, Br or I
- R 2 i$ H a Ci to C 6 alkyl, an alkenyl or an alkynyl., where the Q to C$ alkyl, alkenyl or alkynyl may be optionally substituted; or
- each R 2A is independently selected from the group consisting of H, Ci to C 6 alkyl, alkenyl, alkynyl, aryl, cydoalkyl and arylalkyl, where the Ci to C 6 alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl maybe optionally substituted;
- R 3 is H or halo;
- each R 5 is independently selected from the group consisting of halo, -CHs, -CN, -OCH 3 , -SCH 3 and -CH 2 CH 3 , where the -CH 3 , -OCHj, -SCH 3 Or-CH 2 CH 3 may be optionally substituted; and n is i, 2, 3, 4 or 5.
- M can, for example, be selected from the group consisting of zinc ion, cobalt i ⁇ n, nickel ion, magnesium ion, copper ion and calcium ion.
- the heterocyclic* base comprises one or more N atoms.
- the heterocyclic base is optionally substituted.
- the heterocyclic base may, for example, be selected from the group consisting of isoquinolyl, quinolyl, piperidinyl, pyridinyl, 2-r ⁇ ethylpyridinyl, imadazoyl, pyranyl, pyrrolyl, pyrimidinyl, indolyl, purinyl and quinolizinyl.
- the heterocyclic base is quinolyl.
- metal complex i$ a complex of formula (8) as follows:
- M is a monovalent, divalent, trivalent, tetravalent, pentavalent or hexavalent metal ion; each L s is independently selected and is amonodentate carboxylate, (preferably Indo, ACM or Keterolac) or fl ⁇ amide ligand (O or N bound) (preferably a derivative of Indo, ACM or Keterolac), having anti-inflammatory activity; each L 6 is independently selected and is NH3, a monodentate ligand, a polydentate ligand, or a macrocyclic ligand; m is 1, 2, 3 or 4 n is O, l, 2 ? 3 ? 4 or 5; a ⁇ d p is the charge of the complex.
- the metal complex is a metal complex of formula (8a) as follows: wherein
- the metal complex is a complex of formula (9) a$ follows:
- the metal complex is a complex of formula (11) as follows:
- the metal complex is a complex of formula (12) as follows:
- M is a monovalent, divalent, trivalent, tetravalent, pentavalent or hexavalent metal ion; each L s is independently selected and is a monodentate or bidentate carboxylate, or monodentate amide ligand (O or N bound), having anti-inflammatory activity; each L 7 is independently selected and is a monode ⁇ tate or a polydcntate ligand; each L 8 is independently selected and is a bridging ligand, such as an oxo, hydroxo, carboxylatc (including a N SAID), halide, or other bridging group.
- One or more of the ligands L s and L 8 in any combination may also form dimeric, trimeric, tetrameric, oligomeric or polymeric complexes with one or more metal ions.
- the ancilliary ligands can be chosen from ligands that exert a separate anti-inflammatory activity.
- the metal complex may be administered to the mammalian subject alone or in combination with other antiinflammatory drug(s), or anti-diabetic drugs or treatments for diabetes.
- Such administration can be given to improve the response to the other anti-inflammatory drug(s) » or anti-diabetic drugs or treatmei-t(s), or to reduce the dose of such other drug(s) to reduce toxic $ide-effect$ while maintaining a comparable efficacy.
- the metal complex can be administered to the mammalian subject alone or in combination with other anti- inflammatory drug(s), or anti-diabetic drugs or treatments for the simultaneous treatment of diabetes and conditions associated with diabetes, such as cardiovascular disease and other inflammatory conditions as described in the Applicants co-pending International Patent Application entitled “Prophylaxis or treatment of cardiovascular inflammation” filed 27 March 2007, and co-pending International Patent Application entitled “Metal complexes having anti-inflammatory activity” filed 26 March 2007, the contents of both of which are incorporated herein by cross-reference in their entirety.
- Such administration can be given to improve the response to the other anti-inflammatory drug(s) or anti-diabetic drugs or treatments), and/or to reduce the dose of such other drug(s) to reduce toxic side-effects while maintaining a comparable efficacy.
- the ligand(s) of ⁇ c metal complex used in a method embodied by the invention may not have anti-inflammatory activity alone, the activity being provided by the combination of the metal and the ligand(s) in the complex,
- Methods of the invention find broad application in the prophylaxis or treatment of diabetes.and pre-diabetic conditions,
- the present invention also provides the use of a complex of a metal and a carboxylate, or a derivative of a carboxylate, having anti-inflammatory activity in the manufacture of a medicament for the prophylaxis or treatment of diabetes in a mammalian subject, the carboxylate or derivative being other than salicylate or a derivative of salicylate.
- the diabetes treated by one or more methods embodied by the invention may be selected from the group including, but riot limited to, Type 1 diabetes mellitus, Type II diabetes mellitus, gestational diabetes mellitus (GDM), insulin-dependent diabetes, non-insulin dependent diabetes, juvenile onset diabetes, late onset diabetes, maturity- onset diabetes of the young (MODY), insulin sensitive diabetes, insulin deficient diabetes, carbohydrate intolerance, and diabetes associated with a disease or condition (eg,, such as polycystic ovary disease or acanthosis nigricans), and non-resistant forms of diabetes observed following pancreatic surgery and for instance, following trauma to the pancreas (eg., as a result of injury).
- a disease or condition eg, such as polycystic ovary disease or acanthosis nigricans
- non-resistant forms of diabetes observed following pancreatic surgery and for instance, following trauma to the pancreas (eg., as a result of injury).
- chelating derivatives of NSAIDs can also enhance the stability of metal-NSAlD complexes. This can result in one or more of: (i) a reduction in GI toxicity by increasing the stability of the drugs in the
- a copper hydroxamate complex can exert anti-inflammatory activity by a combination of independent COX-2 inhibition (by both the parent NSAID and the NSAlDHAH 2 ), the release of NO from the NSAlDHAH 2 , 5- lipoxyge ⁇ ase inhibition by the hydroxamic acid, and the effects of Cu once the complex decomposes at a target site.
- metal ions, co-ligands and 0 metal oxidation states of the metal complexes can be utilized to optimise the rate of release and/or hydrolysis of the NSAID-derivative to enable sufficient stability before the anti-inflammatory Iigands of the metal complex are released.
- metal-NSAID complexes with a variety of different metal ions can allow allow a therapeutic regime to be tailored to the type of diabetic condition being S treated.
- Lipophilic formulations containing metal complexes are particularly beneficial fot delivery of lipophilic complexes as described herein.
- Metal complexes can also be provided in water-soluble form for optimized systemic delivery by intravenous injection.
- Metal complexes used in at least some embodiments of the invention will have 0 reduced toxicity associated side effects compared to ligand(s) in the metal complex (eg carbo ⁇ ylate$, hydroxamates, hydroximates, esters and amides).
- the metal complex can have substantially less gastrointestinal and/or renal toxicity than the parent anti-inflammatory ligand.
- the metal complexes can be administered more safely at normal therapeutic doses, or in higher dosages (eg., for acute conditions) and/or over longer periods of time resulting in increased efficacy in treatment.
- one or more methods embodied by the invention can provide an alternative prophylactic or therapeutic treatment for the treatment of diabetes and pre-diabetic conditions which avoid or reduce the adverse cardiovascular side-effects associated with the use of selective COX-2 NSATDs.
- metals used in complexes as described herein and particularly Cu and V can have beneficial cardiovascular effects.
- Pre-diabetic conditions include, for example, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and gestational diabetes.
- Figure 1 shows the chemical structure of [Cu ⁇ IndoMDMF ⁇ J
- Figure 4 is a graph showing plasma haptoglobin following dosing of rats with equimolar Indo doses of IndoH and [Cu 2 (Indo)4(DMF)a] in 2% w/w CMC compared with control rats treated with CMC only ⁇ n - 4; Mean ⁇ SEM).
- Plasma was obtained by cardiac puncture and the haptoglobin level was measured using a commercial kit (Bade Behring, Mannheim, Germany);
- Figure 5 is a graph showing the extent of small intestinal ulceration following treatment of rats with equimolar Indo doses of IndoH or [Gu 2 (Indo) 4 (DMF) 2 ] in 2% w/w CMC compared with control rats treated with CMC only (n ⁇ 4; Mean ⁇ SEM). Ulceration was measured 24 h after dosing;
- Figure 6 is a graph showing the extent of small intestine permeability as determined by the % 51 Cr-EDTA excretion in urine collected for 0-24 h after dosing of rats with equimolar Indo doses of IndoH or [Cu2(Indo>4(DMF)2] in 2% w/w CMC compared with control Tats treated with CMC only (n - 4; Mean ⁇ SEM);
- Figure 9 is a graph showing the extent of mitochondrial DNA damage in rat intestinal tissue after administration of single doses equimolar Indo doses of IndoH or
- Figure 11 is a graph of gastric damage (mm 2 ) for active ingredients (Samples S P, Q and R) dosed by means of oral gavage with a composition of MCT organogel and at Indomethaci ⁇ i Equivalence treat rate of 2 mg kg "1 bw.
- Figure 12 is a graph of the anti-inflammatory effect on rat paw oedema (% ⁇ mm 3 ) of active ingredients (Samples P, Q and R) dosed by means of oral gavage with a composition of MCT organogel and at an Indomethacin Equivalence treat rate of 2 mg 0 kg "1 bw.
- Figure 13 is a graph showing the ability of the vanadium (V) complex [V v O(IndoHAH) 2 (OMe)j (4 mg oxametacin equivalents per kg of body weight) to decrease blood sugar levels in diabetic rats,
- a reference to “copper indomethacin” or “Culndo” is a reference to [Cu 2 (Ind ⁇ ) 4 (DMF) 2 ].
- a reference to “Ibup” is a reference to Ibuprofen;
- a reference to “Im” is a reference to imidazole;
- a reference to “Py” is a reference to pyridine;
- a reference to “3-pic” is a reference to 3-picoline;
- a reference to “4-pic” is a reference XQ 4- ⁇ icoline;
- a reference to “Bim” is a reference to benzimidazole;
- a reference to "IndoH” is a reference to indomethacin;
- a reference to "AcSHAHj” is a reference to aectylsalicylhydroxa
- halo refers to fluoro, chloro, bromo or iodo.
- alkyl used either alone or in a compound word such as “arylalkyi”, refers to a straight chain, branched or mono- or polycyclic aikyl.
- straight chain and branched alkyl examples include methyl, ethyl, propyl, /s ⁇ -propyl, butyl, ⁇ o-butyi, sec-butyl, tert-butyl, amyl, tsoamyl, jec-amyl, 1,2-dimcthyl ⁇ ropyl, 1,1- dimethylpropyl, hexyl, 4-mcthylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpcntyl, 1,1-dimcthylbutyl, 2,2-dimethylbutyU 3,3-dimethyIbutyl,
- cyclic alkyl examples include cyelopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- cycloalkyl refers to a saturated monocyclic or polycyclic alkyl having 3 to 12 carbons.
- alkenyl refers to a straight chain, branched or cyclic alkenyl with one or more double bonds.
- the alkenyl is a Ch. to C20 alkenyl, more preferably a Ca to Q alkenyl.
- alkenyl examples include vinyl, allyl, 1 -methyl vinyl, butenyl, ⁇ ro-but ⁇ yl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methylcyclo ⁇ entenyl, 1-hexenyl, 3-hexenyl ⁇ oyolohexenyl, 1-he ⁇ tenyl, 3-he ⁇ tenyl, 1-octcnyl, cyclooctcnyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl,
- alkynyl refers to a straight chain, branched or cyclic alkynyl with one or more triple bonds, preferably a Cz to C2 0 alkynyl, more preferably a C 2 to C & alkynyl.
- aryl used either alone or in compound words such as “arylalkyl”, refers to a radical of a single, polynuclear, conjugated or fused aromatic hydrocarbon or aromatic heterocyclic ring system.
- aryl include phenyl, ⁇ aphthyl and fiiryl.
- the aromatic heterocyclic ring system may contain 1 to 4 heteroatoms independently selected from N, O and S and may contain up to 9 carbon atoms in the ring.
- arylalkyl refers to an alkyl substituted with an aryl group.
- An example of arylalkyl is benzyl.
- the term "bidentate ligand” refers to a ligand having two co-ordination bonds to a metal atom. Bidentate ligands include unsymmetric bidentate ligands with one weaker and one relatively stronger bond to the metal atom.
- the terra "monodentate ligand” refers to a ligand having a single co-ordination bond with a metal atom.
- the present invention steins from the recognition that at least some metal complexes and in particular complexes of a metal and a carboxylate, hydroxamate, hydroximate, ester or amide having anti-inflammatory activity are effective in the prophylaxis or treatment of diabetes, and can be more effective in treating diabetes in terms of efficacy and/or safety than the carboxylate, hydtoxamate, hydroximate, ester or amide having anti-inflammatory activity itself.
- complexes of a metal and indomethacin may be more effective in the prophylaxis or treatment of cardiovascular inflammation, in terms of efficacy and/or safety, than i ⁇ domethacm itself.
- the metal complex used in the method of the invention may, for example, be any of the complexes set out in following Table 1. It will also be understood that copper ion may be substituted with another transition metal ion (eg zinc, nickel, or cobalt ions as described in Copper and Zinc Complexes a$ Anti-Inflammatory Drugs. Dillon, C. T.; . Hambley, T. W.; Kennedy, B, J.; Lay, P. A.; Weder, J. E.; Zhou, Q. in "Metal I ⁇ n$ and Their Complexes in Medication", Vol. 41 of Metal Ions in Biological Systems'; Sigel, A 1 ; Sigel, H,, Eds.; M.
- transition metal ion eg zinc, nickel, or cobalt ions as described in Copper and Zinc Complexes a$ Anti-Inflammatory Drugs. Dillon, C. T.; . Hambley, T. W.; Kennedy, B, J.; Lay, P. A.; We
- Suprofen (+)- ⁇ - ⁇ iethy1-4-(2-thienyl-carbcaiyl) ⁇ henylacetic acid (SupH);
- Tolmcntin l-methyl-5-(p-toluoylHH-py ⁇ role-2-acetic acid (ToIH);
- c DMSO dimethylsulfoxide;
- Naproxen 6- ⁇ )ethoxy- ⁇ - ⁇ nethyl-2-na ⁇ hthaleneaeetic add (NapH);
- Ibuprofen (+)- ⁇ -methyI-4-(is ⁇ propylmet ⁇ yl)benzeneacetic acid (IbuH);
- ⁇ Metronidazole * 2-methyl-5-oitfobenzimidazole s Rufenamic Add — (N-trifluoromefhyl ⁇ henyl)anthranilic acid (FlufenH);
- ⁇ ⁇ iflumic Acid 2-((34rifluo ⁇ omethyl)phenylamino)-3-pyridinecarboxylio acid - ( ⁇ ifH);
- Indomethadn l-(4-chlorobenzoyl)-5-mefhoxy-2-methyl-lH-indole-3-aceti ⁇ acid (IndoH);
- ⁇ SAIDs include: Catprofen (6-chloro-a-methyl-9H-carbazole-2-acetic acid);
- Etodolac (l,8-diethyl-l,3,4,9-tetrahydio-pyrano[3,4-b]indole-l -acetic aoid); Fentiazac (4-(4-chlo «)phenyl)-2-phe ⁇ yl-5-thiazoleaoetJc add); Flurbiprofen (2-fluoro-a-methyl-[l ] r-biphejiyl3-4-acetic acid); Ketoprofen (3-benzoyl-a-methylbenzeneacetic acid); Oxaprozin (4,5-di ⁇ henyl-2-oxazol ⁇ propanoic acid);
- Pranoprofen (a-mcthyl-5H-[l]benzopyrano[2 t 3-b]pyridine-7-acetic add); Sulindac ((12)-5-fluoro-2-methyl-l-[[4-(inethylsulfinyl)phenyl]methylene]- lH-indene-3 -acetic acid); and
- Metal complexes useful in methods embodied by the invention can be prepared by methods known in the art, or prepared by methods described below. Methods known in the art are described in, for example, United States Patent No, 5,466,824 or the paper: Anti-inflammatory Dinuclear Copper(II) Complexes with Tndomethacin. Synthesis, Magnetism and EPR Spectroscopy, Crystal Structure of the N,N-Dimethylformamide Adduct Weder, I E.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.; MacLachlan, D.; Bramley, R 1 ; Delfs, C. D.; Murray, K, S,; Moubaraki, B.; Warwick, B.; Biffin, J.
- the complex can be a complex comprising at least one metal ion and at least one hydroximate, hydroxamate, ester or amide derivative of a carboxylate NSAID having anti-inflammatory activity.
- a hydroxamic acid having anti-inflammatory activity can form hydroxamato or hydroximato complexes with a metal ion in the complex.
- An amide having anti-inflammatory activity can for example, also form chelates of deprotonated amides or amide monodentate complexes with a metal ion in the complex.
- Inert metal complexes incorporating carboxylate ligands having inflammatory activity can be prepared by methods known in the art, or as described below. Such reactions include the substitution of a leaving group in an inert metal complex with a carboxylate group of an NSAID, or an amide group in a NS AID or an amide derivative of a NSAID, This i$ exemplified by Example 1 in the preparation of [Co(NH 3 )s(Indo)]X ? as follows:
- M Co(IlD, Cr(IIT), Tr(ITT), Os(ITT), Rh(ITI),
- such complexes can be prepared by substitution of a weakly coordinated, trifluoromethanesulfonato, or solvent, or other such ligands, as described for example in, Introduction to Trifluoromethanesulfonates and
- m etal complexes of the invention can be prepared by reaction of a derivative of R 6 COZ with a hydroxo or deprotonated amine ligand on the metal, for example: [MCOHUL 6 ),/ + mR 6 C0Z ⁇ [M(L 5 ) ra (L 6 ) n ] p + mZ
- esters of carboxylates having anti- 5 inflammatory activity and amide derivatives of carboxylates that bind in a m ⁇ n ⁇ dentate fashion to the metal.
- the esters and amides can contain heterocyclic groups or aliphatic or aromatic groups that contain other functional groups that bind to the inert metal in a mo ⁇ odentate fashion,
- a monodentate amide Iigand can bind via O to the metal ion or deprotonate and bind via N to a metal ion in the complex, as described in: Fairlie, D. P.; 0 Han, Y,; Taube, H, Oxygen versus Nitrogen Bonding of Carboxamides to
- Oxygen and nitrogen-bownd forms of the amide complexes can be interconverted by a change pH or other means of pr ⁇ tonatio ⁇ /deprotonation reactions, for example:
- X is a conjugate base of a strong or a weak acid (eg., X can be a halide, oxyanion, carboxylate, sulfonate, etc.);
- X J is a conjugate base of a weak acid, examples of which include oxyanions, carboxylates, amines, and N- 0 heterocycles;
- Y is a leaving group, examples of which include halo, alkylsulfonato, O- bound sulfoxides, 0-b ⁇ und amides, aldehydes, ketones, and nitrato ligands; and
- R 6 COZ is an acyl halide, anhydride or ester derivative of a NSAID.
- Metal complexes embodied by the invention can also be prepared by methods outlined in Example 1 below.
- the complexes contain Indo, ACM, ketorolac or derivatives of Indo, ACM or ketorolac ligands as described above, or amide or ester derivatives of these or other NSAIDs.
- the functional groups of the ligands can themselves bind to the metal ion, and/or other ligating groups that are linked by these functionalities can bind to the metal.
- any R group (eg., alkyl, aryl etc) of an amide derivative can also contain donor functional group(s) that form a co-ordination bond with a metal ion.
- Such functional groups include, for instance, a carboxylate group of an amino acid or peptide derivative of a NSAlD, or a RS " , thioether, phenol, amine, or iV-heterocyclic side-chain of such an amino acid or peptide derivative. It will also be understood that a large variety of other functional groups would be suitable.
- Hydroxamic acids having anti-inflammatory activity that may be utilised in the complexes used in the method of the invention include those of the type described in International Patent Application No. WO 2004/000215 comprising a NSAID covalently linked by a linker to a hydroxamate.
- Hydroxamic acid derivatives of carboxylates having anti-inflammatory activity such as Indo and esters of lndo (e.g. ACM), are particularly preferred.
- R AIk or Ar hydroxamato hydroximato complex complex
- Amide derivatives of carboxylic acids having anti-inflammatory activites can be prepared as described in International Patent Application No. WO 95/04030, or modifications thereof. See, for instance, the indomethacin example below (Scheme 2).
- R may be a proton, alkyl or aryl group, in which case the liga ⁇ d would be a monodentate O or N donor to the metal.
- R may contain one or more functional groups that could act as other donor groups to form a metal chelate.
- Suitable coupling reactions include those with amino acids to form a mixed amide/carboxyiate donor set (or a stagentate or bidentate carboxylase donor only), or more complex donor bidentate sets with amino acids containing metal binding side-chains, e.g., cysteine, serine, methionine, histidine, tyrosine, etc.
- Other suitable R groups include amino sugar derivatives and glycoproteins that target tumour cells *
- the coupling reaction may also involve short chain peptides, which can act as chelating ligands, or other groups to give metal chelators with anti-inflammatory activities, as described in WO 95/04030.
- R may be an alkyl or aryl group containing a substituent, which can act as a monodentate or polydentate Hgand, e.g., a carboxylate group as in ACM, Of an amino group (prepared from an aminoalcohol) with a monodentate or polydentate amine ligands Of more complex donor bidentate sets with serine or short-chain peptides containing serine.
- chelating groups that may be coupled, include sugars and glycoproteins.
- the ligand having anti-inflammatory activity is an amide-containing NSAID that i$ not a carboxylate.
- NSAIDs that are not carboxylates include for instance ⁇ xicam NSAID$ such as piroxicam (4-hydroxy-2-methyl-N-2- pyridyl-2H- l ⁇ -ben ⁇ oihiazine-3-carboxamide- 1,1 -dioxide), tenoxicam (4-hydroxy-2- methyl-N-2-py ⁇ dinyl-2H ' iMeno(2,3-e)-l ⁇ -thiazine-3-carboxamide-l,l-dioxide) and meloxicatn.
- the complex is a complex of the formula (A);
- M is a metal ion
- L 4 is a hydr ⁇ xamate or hydroximate having anti-inflammatory activity or a chelating amide (such as those containing an amino acid or peptide linkage as the chelate) having anti-inflammato ⁇ y activity; each L is independently selected and is a monode ⁇ tate or polydentate ligand; n is l, 2 or 3; m is 0, 1» 2, 3 or 4; and p is the charge of the complex,
- M is a divalent, trivalent, tetravalent, pentavalent or hexavalent metal ion
- NSAIDs and NSAlD ligands that may be utilised are described in for instance Wcdcr. J. E.; Dillon, C. T.; Hambley, T. W,; Kennedy, B. J.; Lay, P. A.; Biffin, J. R.; R ⁇ gtop, H. L., Davies.; N. M. Coord. Chem, Rev. 2005, 232, 95-126 and Dillon, G. T.; Hambley, T. W.; Kennedy, B. J.; Lay, P.
- the complex used in the method of the present invention may be a mononuclear, dinuclear, trinuelear, oligomeric or polymeric complex containing the ligand L 2 as defined above.
- the complex may be a complex of formula (1), (2), (3) or (8), as defined above.
- Complexes of formula (1 ) or (2) can be prepared by mixing a stoichiometric amount of a compound L 2 H (where L 2 is as defined above) and a divalent or trivalent metal salt, preferably a ba$ic salt such as M(OAc) 2 , in a solvent L (the solvent forming the ligand L in the resultant complex, or in the case of the aqua complex, adventitious water in the organic solvent). The mixture is then heated until precipitation occurs and it is then cooled and the solid is filtered off.
- a compound L 2 H where L 2 is as defined above
- a divalent or trivalent metal salt preferably a ba$ic salt such as M(OAc) 2
- the product may need to be recrystallised until elemental, spectroscopic and/or diffraction methods demonstrate that the complex is of the required purity
- Complexes of formula (3) can be prepared by the same procedures as those described above for the preparation of complexes of formula (1) or (2) using a trivalent or tetravalent metal salt. Such complexes are obtained by mixing L 2 H and a suitable metal salt in aqueous/organic solvent mixtures under basic conditions. Additional ligands L may be added to these solutions to precipitate the complexes. Methods of preparation of complexes of formula (I) 1 (2) and (3) are discussed in the Applicants co-pending International Patent Application No. PCT/AU2006/000391, the contents of which arc incorporated herein by cross-reference in it$ entirety. The complexes of formulae (1), (2) or (3) may be charged or neutral.
- Complexes of formula (1) and (2) are neutral in charge if M is a divalent metal ion and all the Hgands L are neutral Ugands.
- a complex of formula (1) or (2) may have a charge, for example, p may be 1 " or 2 " .
- Complexes of formula (3) have a charge of I + if all the metal ions M' in the complex are trivalent metal ions and all the ligands L are neutral. However, in some embodiments, the complex of formula (3) may have a charge of T, V, O 7 or 2 * .
- Examples of complexes of formula (1) include [Cu(ACM) 2 (DMFh] * [Cu(ACM) 2 (OHa) 2 ], [Zn(ACM) 2 (DMF) 2 ] and [Zn(ACM) 2 (OH 2 ) 2 ].
- Examples of complexes of formula (2) include [Cu 2 (ACM) 4 L 2 ], [Zn 2 (ACM) 4 L 2 ], [Ru 2 (ACM) 4 L] p and [Ru 2 (ACM) 4 L 2 ] p (where Ru is Ru(II)X and
- the complex of formula (2) is a complex of the formula (2A):
- the complex i$ a mononuclear complex of the following S formula (4):
- the mononuclear complex of formula (4) is a complex of formula (4A):
- the complex of formula (4) may be charged or neutral, Preferred complexes include [Cu(UIdO) 2 (Im) 2 ], [Cu(ACM) 2 (OH 2 ) 2 ], [ZnOndoMOrfek] ⁇ nH 2 O and [Z ⁇ (ACM) 2 (OH 2 ) 2 ].
- the complex of formula (4) can be in solution, or may be in the form of a solid. 0 Crystals of a complex of formula (4) may include solvent$ of crystallisation. Crystals of a complex of formula (4) may also include waters of crystallisation. If L is an anionic ligand, the complex of formula (4) will be charged (e,g., p is 1 ⁇ or T) and a solid of the complex of formula (4) will include cations that are counter ions to the anionic complexes.
- Such solids include solids having the following formulas: 5 YtMdf-L'fel ⁇ ] (4B) and wherein M, ⁇ 2 ⁇ lJ and L are as defined above for formula (4A), Y is a counter ion having a 2 + charge and Y ' is a counter ion having a I + charge.
- Complexes of formula (4) where M is Cu(U) can, for example, be formed using the ligand pyrrolidine.
- Other ligands having a similar donor strength to, or a greater donor strength than, pyrrolidine can also form complexes of formula (4).
- L is a ligand containing an N-heterocyclic group.
- Ligands containing an N-heterocyclic group include pyrrolidine, alkyl-substituted pyrrolidines, proline, proline derivatives, imidazole, imidazole derivatives $uch as substituted imidazoles or ligands containing an imidazole ring (eg.
- L is an amine, e.g. NH 3 or an organic amine (e.g. diethylamine), an alcohol or an amide (e.g. diethylacetamide), or another ligand that is a strong donor such as ttiethylphosphate.
- L can be a solvent having a solvent donor number of about 30 or greater.
- Complexes of formula (4) may, for example, be prepared by direct reaction of the appropriate ratios of a compound of the formula L 1 H where L 1 is as defined above and a copper salt such as copper(H) acetate in a solvent having a solvent donor number of about 30 or greater, the solvent forming the ligaad L in the resulting complex.
- Complexes of formula (4) may also be prepared by adding a solvent having a solvent donor number of about 30 or greater, or adding a ligand that is not a solvent but has a similar donor strength to a solvent having a solvent donor number of about 30 or greater, to a solution of the metal ion (e.g. Cu(D)) and L J in a weaker donor solvent.
- complexes of formula (4) can be prepared by re-crystallisation of a dinuclear complex, $uch as [Cu 2 (ItIdO) 4 (DMF) Z ] * in a solvent having a solvent donor number of about 30 or greater, such as pyrrolidine, or in a solvent containing a ligeuid that is a strong donor such as imidazole (Im).
- the complexes of formula (4) are. more lipophilic than indomethacin or other compounds of the formula L 1 H and thus are more easily absorbed through membranes and taken up by tissues locally.
- the complexes of formula (4) are, therefore, expected to be more readily absorbed into cells than free indomethacin or other compounds of the formula L 1 H when administered topically.
- the complex is a dinuclear complex of the formula (5):
- Complexes of formula (5) may be charged or neutral in charge.
- the ligand L may be any monodentate ligand.
- the ligand L may be charged or uncharged.
- L may, for example, be water (OH2), an alcohol, dimethylsulfoxide (DMSO), pyridine (Py), acetotiitrile (AN), tetrahydrofuran (THF), or L may be a ligand containing a tertiary amide or cyclic tertiary amide.
- L may be a molecule of a tertiary amide of the formula
- Ri i$ an alkyl having from 1 to 4 carbon atoms, and each Ri may be the same or different, and R 2 is a cycl ⁇ alkyl having from 2 to 7 carbon atoms.
- the tertiary amide or cyclic tertiary amide may be, for example, JV.N-dimethylformainide, N,N-dimethylacetamide or N-methylpyrroIidone.
- An example of a complex of formula (5) is a dimiclear complex of the formula (5A):
- M is Cu or Zn; each L is independently selected and is a nio ⁇ odentate ligand; and p is the charge of the complex.
- L 1 may for example be Indo.
- the complex is a dinuclear metal/indomethadn complex of the formula (5B):
- M 2 ( ⁇ -I ⁇ do)4Y 2 j 5B
- M is Cu or Zn
- Indomethacin is one of the most lipophilic NSATOs and, again without being 5 limited by theory, the present inventors believe that the binding of the ligand to a metal makes complexes of formula (5B) more lipophilic than IndoH and hence promotes the transport of M (i.e. Cu or Zn) and Indo into the vasculature (i.e. there is greater absorption of the complex than IndoH).
- M i.e. Cu or Zn
- Indo into the vasculature i.e. there is greater absorption of the complex than IndoH.
- the greatly reduced adverse effects of the complex compared with free indomethacin such as gastrointestinal and 0 particularly, the newly discovered reduction in renal effects on oral administration as described herein
- Complexes of formula (5B) include, for example, [Cu 2 (IUdO) 4 (DMFh], [Cu 2 (Indo) 4 (DMA) 2 ], [Cu 2 (UIdO) 4 (NIVlP) 2 ], [Cu 2 (LIdO) 4 (DMSO) 2 ], [Cu 2 (IiIdO) 4 (THF) 2 ], 5 [Cu 2 (LIdO) 4 (Py) 2 ], [Cu 2 (IBdO) 4 (AN) 2 ], [Cu 2 (Indo) 4 (OH 2 ) 2 ] ? [Cu 2 (Ket) 4 (OH 2 ) 2 ] s
- NMP N-methylpyrrolidone
- a preferred complex is [Cu 2 (Indo) 4 (OH 2 ) 2 ],nH 2 0, wherein n is the number of waters of crystallisation.
- the number of waters of crystallisation will vary depending on O the technique used to prepare the complex, and is typically from 1 to 5.
- Complexes of formula (5) may be prepared by methods known in the art.
- copper(H) and zi ⁇ c ⁇ II) complexes with indomethacin may be prepared as described in United States Patent No. 5,466,824 or a$ generally described in the paper: Anti-inflammatory Dimiclear Copper(II) Complexes with Indomethacin. Synthesis, 5 Magnetism and EPR Spectroscopy; Crystal Structure of the ⁇ T,N-Dimethylformamide
- the complex is a trinuclear complex of the following formula ( ⁇ ):
- each M' is independently selected and is a trivalent or tetravalent metal ion; and ⁇ -L 1 , L and p are as defined above for formula (5).
- Trinuclear metal complexes with the llgand L 3 and L 4 Trinuclear metal complexes with the llgand L 3 and L 4
- the complex is a trinuclear complex of the following formula (7):
- L 3 is a carboxylate having anti-inflammatory activity
- L 4 is an optionally substituted heterocyclic base comprising one or two heterocyclic rings independently having 5 or 6 ring members and 1 to 3 heteroatoms independently selected from N, O and S; and wherein each L 3 is independently selected; and each L 4 is independently selected.
- L 3 may be a mo ⁇ odentate, bidentate or bridging ligand of formula L 1 or L 2 as follows: wherein:
- R 1 is H or halo (i.e. Cl, F, Br or 1);
- R 2 is H; a C 1 to Ce alkyl, an alkenyl or an alkynyl, where the Cj to C ⁇ alkyl, alkenyl or alkynyl may be optionally substituted; or
- each R 2 ⁇ is independently selected from the group consisting of H, Ci to Cs alkyl, alkenyl, alkynyl, aryl, cyclqalkyl and arylalkyl, where the Ci to Ce alkyl, alkenyl, alkynyl, aryl, cycloalkyl or arylalkyl may be optionally substituted;
- R 3 is H or halo; each R s is independently selected.from the group consisting of halo, -CH3, -CN, -OCH 3 , -SCH 3 and -CH 2 CH 3 , where Hie -CH 3 , -OCH 3 , -SCH 3 or -CH 3 CH 3 may be optionally substituted, and n i$ 1 , 2, 3, 4 or 5.
- R 2 is a Ci to C 6 alkyl, an alkenyl or an alkynyl, the Ci to
- Co alkyl* alkenyl or alkynyl may be substituted with one or more sub$tituent$.
- the one or more substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 .
- R 2A is a Ci to C 6 alkyl
- the Ct to Ck alkyl, alkenyl, alkyayi, aryl, cycloalkyl or arylalkyl may be substituted with one or more substituents.
- the one or more 5 substituents may, for example, be independently selected from the group consisting of halo, -OH, -COOH and -NH 2 ,
- Tn formula (7) when R 5 i$ -CH 3 , -OCH 3 , -SCH 3 or -CH 2 CH 3 , the -CH 3 , -0CH3, -SCH 3 or -CH 2 CH 3 may be substituted with one or more substituents.
- the one or more substituents may, for example, be independently selected from the group 0 consisting of halo, -OH, -COOH and -NH 2 .
- R 1 i$ typically H.
- R 3 i$ typically H.
- R 2 is typically CH 3 .
- L 2 is ACM. 5
- M may be selected from the group consisting of zinc, cobalt, nickel, magnesium, copper and calcium.
- the heterocyclic base comprises one or more N atoms. In some embodiments, the heterocyclic base is optionally substituted.
- the heterocyclic base may be selected from the group consisting of isoqui ⁇ olyl, O quinolyl, piperidinyl, pyridinyl, 2-methylpyridinyl, imadazoyl, pyranyl, pyrrolyl, pyrimidinyl, fndolyl, purinyl and quinolizinyl.
- the heterocyclic base is quinolyl.
- the ligands of these complexes comprise carboxylate ligands, or derivatives of carboxylates, having anti-inflammatory activity such as hydroximate, hydroxamate, hydrazine, amide, or ester derivatives having anti-inflammatory activity.
- Metal complexes of these formulae can for instance, be prepared by methods outlined in Example 1 of this application or by other suitable synthesis methods.
- the metal O complexes can, for instance, include ligands L 1 and L 2 as described above, ketorolac or other NSAID as described herein, or their hydroximate, hydroxamate, hydrazine, amide, or ester derivatives.
- the functional groups of the ligands can themselves bind to the metal ion, and/or other ligati ⁇ g groups that are linked by these functionalities can bind to the metal.
- the metal comlexes can be inert or labile complexes.
- the metal ion or metal ions of inert complexes have an inert oxidation state.
- the metal complex is a complex of formula
- each L 5 i$ independently selected and is a monodentate carboxylate (preferably T ⁇ do > ACM or Keterolac) or an amide ligand (O or N bound) (preferably a derivative of I ⁇ do, ACM or Keterolac), having anti-inflammatory activity; each L 6 is independently selected and is NHj, a monodentate ligand, a polydentate ligand, or a macrocyclic ligand; m i$ l 5 2 ⁇ 3 ⁇ r4 n is O, 1, 2, 3, 4 or 5; and p is the charge of the complex.
- L 5 is NH3 or a monodentate, polydentate, or macrocyclic amine ligand.
- Preferred complexes of formula (8) include [M(O 2 CR 1 O 1H (NR 9 R 111 R 1 Vm/ where M is selected from Co(III), Cr(IH) 5 Ir(III), Os(UI), Rh(III), Ru(IIl) or Pt(IV) and more preferably, Co(HI), Cr(III), or Ru(III), and R 6 CO 2 " is an anti-inflammatory NSAID such as exemplified above, and R 9 , R 10 and R 1 ' can independently be H or an optionally substituted aliphatic or aromatic group.
- L 5 is NH 3 or a monodentate, polydentate, or macrocyclic amine ligand.
- Preferred complexes of formula (S) include: [M(L 1 X n (NR 9 R 10 R 11 ), ⁇ where L 3 is independently chosen from a NSATD, R 6 CO 2 " , R 6 CON(RY or an amide (R 6 CONR 7 R*) or ester derivative 5 (R 6 COOR 8 ) of a NSAID, (KR 9 R 1 V x ) is individually selected from monodentate or polydentate amine tigands, and M is selected from Ru(II), Co(III), Cr(III) * MHI), Os(III), Rh(III), Ru(III) and Pt(IV) and more preferably, Ru(D), Co(III), Cr(IH), and Ru(III); (M(L s ) ra (0H s ) n f where L s is independently selected from a NSAJ
- the metal complex is a complex of formula (8a): .
- M is selected from Co(Hl), Cr(Ul), Ir(UI), Os(IIT), Rh(III), Ru(III) and Pt(IV) and more preferably, Co(IU), Cr(IIl), and Ru(III); [M(L ⁇ (NR 9 R 10 R 1 ') 3 ] p where L 6 is a tridentate 0 derivative of an N SAID, each (NR 9 R 10 R 1 ') is independently a monodentate amine ligand or polydentate amine Hgand, and M is selected from Co(III), Cr(III), Ir(III), Os(III), Rh(III), Ru(TII) and Pt(TV) and more preferably, Co(III), Cr(IH), and Ru(Hl); [M(L 6 )(NRV°R n ) 2 ] p where L 6 is a tetradentate derivative of an NSAJD, (NR 9 R 10 R 11 ⁇ is two independently selected monodentate amine ligands or a
- S M is a monovalent, divalent, trivalent, tetravalent, pentavalent or hexavalent
- each L 7 is independently selected and is NH 3 , a monodentate ligand, a polydentate ligand, or a macrocyclic ligand
- each L 8 is independently selected and is a chelating derivative of a carboxylate 0 such as a hydroximate, hydroxamate, hydrazine, ester, amino acid, peptide or sugar, or amide chelating ligand (O or N bound), having anti-inflammatory activity, 5; n is 1, 2, 3 or 4; and p is the charge of the complex. 5
- L is NH 3 or a monodentate, polydentate, or macrocyclic amine ligand.
- Preferred complexes of formula (2) include [M(NR 9 R 10 R 1 ')( 6 - 2 ⁇ )(L 8 )J p when L s is a bidentate Hgand, [M(NR 9 R 10 R 1 ') 3 (L 8 )3 P when L 8 is a tridentate ligand, and [M(NR 9 R 10 R 1 ') 2 (L S )] P when L* is a tetradentate ligand, where M is selected from Co(III), Cr(III) J Ga(III), Ir(III), 0 Os(III), Rh(III), Ru(IlI), Ru(Il) and Pt(IV) and more preferably, Co(III), Cr(DI), Ga(III),
- Ru(III) and Ru(Il), and R 9 , R 10 , and R 11 are as defined for formula (8 or 8a) above.
- the metal complex of formula (9) can be [M(NR 9 R 10 R 11 J 2 (I/)] 11 where L 8 is a bidentate ligand, [M(NR 9 R l0 R u )(L 8 )] p where L 8 is a tridentate ligand, and where M is Cu(II), Ni(II), Pd(II), Pt(II) or Au(III) and more preferably Cu(II), and R 9 , 5 R 10 , R" and R 5 are as defined for formula (8 or 8a) above.
- the metal complex is [M(L 8 )a] p .
- L 8 is a bidentate ligand ri is 3, or when L s is a tridentate ligand n is 2, and wherein M is preferably Co(IH), Cu(II), Zn(II) 5 Ga(IH), Ru(HI), or Ru(II); or when L* is a bidentate ligand n is 2, or when L 8 is a tetradentate ligand n is 1, wherein M is O preferably Cu(Il), Ni(II), Pd(II), Pt(II) or Au(III) and more preferably Cu(II).
- R 0 , R 10 and R ⁇ of formulae (8a) and (9) can for instance be selected from aliphatic and aromatic groups consisting of substituted or unsubstitutcd alkyl, alkenyl, alkynyl, aryl, ⁇ trylalkyl and heterocyclic groups.
- heterocyclic groups include heterocyclic bases comprising ooe or more N atoms. In some embodiments, the heterocyclic base is optionally substituted.
- the heterocyclic base may for example be selected from the group consisting of isoquinolyl, quinolyl, piperidinyl, pyridinyl, 2- methylpyridinyl, imadazoyl, pyranyl, pyrrolyl, pyrimidinyl, indolyl, purinyl and quinolizinyl.
- metal complexes of formula (9) include [Cn(lndoHAH)(OH)], [Co(en) 2 (lndoHA)]Cl 2 , [Co(en) 2 (I ⁇ doHA)](CF 3 S ⁇ 3 ) 2 ,
- metal complexes (hat can be used in methods embodied by the invention include complexes of formula (10):
- each L 1 is independently selected and is NH 3 , another rno ⁇ dentate ligand, a polydentate ligand, or a macrocyclic ligand
- the metal complex can be a complex of the following formula (11):
- metal complexes of formula (11) for instance, include: [M(O 2 CR 6A )(L 7 ) m (L 8 ) D ] p where, m is 0, 1, 2, or 3, n is 1 or 2, R ⁇ COf is a NSAID, R 6 CO 2 " , or an ester derivative of an R 6 C ⁇ 2 ⁇ NSAID having a terminal carboxylate, at O least one of L 8 is independently selected from a hydroxamate or hydr ⁇ ximate derivative of a NSAlD, an amino acid derivative of a NSAID, a peptide derivative of a NSAID, and an amine derivative of a NSAID, and M is Co(III), Rh(III), Ir(III), Cr(ITI), Ru(III) or Pt(IV), and preferably Co(III), Cr(III), or Ru(III); where, m is O, 1 or 2, n is 1 of 2, R 6 ⁇ C ⁇ 2 ⁇ is independently a NSAID, or an ester or
- each L 5 M is a monovalent, divalent, trivalem; tetravalent, pentavalent or hexavalent metal ion; each L 5 is independently selected and * is a roo ⁇ ode ⁇ tate of bidentate carboxylate, or monodentate amide ligand (O or N bound), having anti-inflammatory activity; 0 each L 7 is independently selected and is a mooodentate o ⁇ a polydentate Hgand; each L 8 is independently selected and is a bridging ligand, $uch as an oxo, hydroxo, carboxylate (including a NSAID), halide, or other bridging group, m is an integer from 0 to 5q; B is an integer from 1 to Sq; 5 p is the charge of the complex; q is typically an integer between 2 and 20 inclusive; and r is an integer from 1 to 60,
- One or more of the ligands L 5 to L 8 above in any combination may also form dimeric, trimeric, tetr&meric, oligomei ⁇ c or polymeric complexes with one or more 0 metal ions,
- L 7 is aN-heterocycle or aqua ligand
- R 11 is a H, alkyl or aryl substituent
- Monodentate ligands which can be used in metal complexes described herein o include monodentate ligand such as halo, aqua, hydroxo, oxo, CO, NO, amines, alcohols, amides, sulfoxides, W-heterocylces, 0-heterocycles, and 5-heterocycles.
- Polydentate acyclic liga ⁇ ds include amines, amino acids, peptides,. alcohol sugars, hydroxyacids, polycarboxylates, N-heterocylces, 0-heterocycles, and S-heterocycles, and functional groups that can form co-ordinate bonds with a metal ion.
- Polydentate macrocyclic ligands include amines, crown ethers, thi ⁇ ethers, macrocyclic peptides and amides, and ligands with, combinations of these and other metal binding substituents.
- bridging ligands that can be utilized in metal complexes as described herein include oxo, hydroxo, carboxylate (including carboxylate NSAIDs), halo and other bridging groups.
- aliphatic and aromatic groups that can be employed include substituted or unsubstitut ⁇ d alkyl, alkenyl, alkynyl, aryl, arylalkyl and heterocyclic 0 groups.
- heterocyclic groups include heterocycles comprising one or more N, O and/or S atoms. In some embodiments, the heterocycle is optionally substituted.
- the heterocycle can for example be selected from the group consisting of isoquinolyl, quinolyl, piperidinyl, pyrldinyl, 2-methyipyridinyI, imadazoyl, pyranyl, pyrrolyl, pyrimidinyl, indolyl, purinyl and quinolizinyl as described above.
- the metal ion of metal complexes that can be utilized in methods embodied by the invention include d-block, f-block, p-block and s-block metal ions.
- the metal M will be a divalent, bivalent, tetravalent, pentavalent or hexavale ⁇ t d-block metal, preferably, Co(II), Cu(II), Fe(II). Mn(II), Mi(Ir), Ru(TI), Zn(Il) 1 Co(IIl), Cr(IIIX Fe(IH), Mn(III) 9 Ru(III), Mn(IV). Mo(IV), Ru(IV), V(IV), 0 Mo(V), V(V), W(V), Mo(VI), or W(VI), or a trivalent or tetravalent p-block metal such as Ga(TH) 7 Bi(TTI) or Sn(TV).
- a trivalent or tetravalent p-block metal such as Ga(TH) 7 Bi(TTI) or Sn(TV).
- Suitable methods for the synthesis of metal complexes are for instance, further described in: (Romakh, V. B.; Therrien, B.; Labat, G; Stoekli-Eva ⁇ s, H,; Shul'pin, G- B.; Suess-Fink, G. Dinuclear iron, ruthenium and cobalt complexes containing 1,4- 5 dimethyl-1 ,4,7-triazacycIononanc ligands as well as carb ⁇ xylato and oxo or hydroxo bridges.
- metal complexes of indomethacin, ibuprofen, naproxen, dichlofenec, ketorolac, and/or derivatives thereof having anti-inflammatory activity are utilised for the prophylaxis or the treatment of diabetes as described herein.
- any suitable such NSAID or derivative thereof can also be utilized.
- the term 'Hherapeutically effective amount means an amount effective to yield a desired therapeutic response, eg prophylaxis or treatment of diabetes or a diabetic condition as described herein.
- the metal can be administered alone or be 0 co-administered in combination with one or more therapeutic agents conventionally used in the treatment of diabetes and pre-diabetic conditions.
- co-administered is meant simultaneous administration in the same formulation or a plurality of formulations by the same of different routes, or sequential administration by the same or different routes.
- sequential administration is meant one is administered one after 5 the other.
- a metal complex in one or more methods embodied by the invention in combination with another anti-inflammatory or therapeutic agent conventionally used for the treatment of diabetes or pre-diabetic conditions may enhance the effectiveness of the other agents or allow the dosage of the other agents to be lowered to reduce toxic side effects of those agents.
- the specific "therapeutically effective amount" of the metal complex utilised in a method embodied by the present invention will vary with such factors as the particular diabetic condition being treated, the physical condition age and weight of the human or animal, the type of animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific composition and complex employed.
- the dosage administered and route of administration will be at the discretion of the attending, clinician or veterinarian and will be determined in accordance with accepted 5 medical or veterinary principles- For instance, a low dosage may initially be administered which is subsequently increased at each administration following evaluation of the response of the subject. Similarly, the frequency of administration can be determined in the same way, that is, by continuously monitoring the response of the subject and modifying the interval between dosages.
- Metal complexes as described herein will typically be administered at a dosage of the metal ion to body weight of the mammalian subject of about 0.1 mmol/kg or less, preferably at a dosage of 0.01 mmol/kg bodyweight or less, more preferably at a dosage of 0.005 mmol/kg bodyweight or less, and most preferably, in a dosage range of from 0.01 - 0.01 mmol/kg body weight. 5 It will also be understood that a plurality of different metal-NS AID complexes as described herein can be administered to the mammalian subject in the treatment of diabetes or pre-diabetic condition.
- the metal complexes can be selected to provide different anti-inflammatory activies and/or have different rates of release of antiinflammatory ligands, 0
- the roetal-NSAID complex(e$) can be administered to the mammalian subject systemicaUy.
- the complex can also be applied topically to the skin for diffusion into the body of the subj ect to the site of action, by oral administration, or by suppository or any other mode of administration suitable for the particular diabetic condition being treated.
- S The complex will generally be administered in the form of a pharmaceutical. composition comprising the complex together with a pharmaceutically acceptable carrier.
- the composition can.
- a lipophilic carrier eg., a medium chain triglyceride (MCT) formulation
- MCT medium chain triglyceride
- a formulation having a colloidal structure as described in International Application No. PCT/AU2005/000442, the 0 contents of which is incorporated herein by eross-referenee in its entirety.
- a formulation having a colloidal structure or which forms a colloidal structure post administration is particularly desirable for administration of - metal complexes.
- compositions having a colloidal structure or which form a colloidal structure upon, or following administration are exemplified in PCT/AU2005/00042 and any suitable such formulations for the selected mode of administration can be utilised in methods embodied by the present invention. Formation of the colloidal structure can for instance occur when the composition contacts an aqueous biological fluid in the human or animal body, for example, on contact with an aqueous fluid in the digestive tract.
- a composition has a colloidal structure if it comprises a colloidal system.
- a colloidal system is a system in which particles of a colloidal size of any nature ⁇ eg., solid as liquid or gas) are dispersed in a colloidal phase of a different composition or state.
- the composition comprises micelles in. an aqueous carrier or is an oil-in-water emulsion, or forms micelles or an oil-in-water emulsion when the composition is administered to a human or animal body.
- the colloidal structure protects the metal complex from interaction with acids or other compounds which would otherwise interact with the complex to cause the complex to dissociate. It is also believed the colloidal structure reduces the extent to which some compounds present in the composition are able to interact with the complex, e.g. during storage of the composition, that may cause the complex to dissociate. Similarly, when such a composition is administered to a subject, the colloidal structure may limit the extent to which some compounds that come into contact with the composition after it i$ administered are able to interact with the complex and which cause the complex to dissociate before it is absorbed.
- the colloidal structure may limit the extent to which compounds present in stomach acid are able to interact with the complex to cause the complex to dissociate before it is absorbed through the gastrointestinal tract.
- the colloidal structure may limit the extent to which compounds that come into contact with the composition after it is administered, e,g. strong chelators of Cu(II), such as peptides, or reductants of Cu(Jl), such as thiol -containing biom ⁇ lecules, are able to interact with the complex to cause the complex; to dissociate.
- compositions may not have a colloidal structure but will be formulated such that when administered to a human or animal body by the intended route of administration, a colloidal structure i$ formed.
- a colloidal structure i$ formed.
- the colloidal structure is maintained for a sufficient time after administration of the composition for the majority, for example more than 70%, 80% or 90%, of the metal complex, to be absorbed by the body as a metal complex.
- Oils for use in the compo$itio ⁇ $ include pharmaceutically acceptable vegetable or mineral oils.
- suitable oils include, but are not limited to: triglycerides, particularly medium chain triglycerides, combinations of medium chain and long-chaio triglycerides, combinations of triglycerides with fish oil; vegetable oils, such as, soya oil, safflower oil and sunflower oils; isopropyl myristate; and paraffins.
- Such oils are suitable for use in compositions for oral, injectable, or topical administration.
- the composition comprises micelles in an aqueous carrier, the composition will typically further comprise one or more surfactants for formation of the micelles.
- surfactants may be used that are capable of forming micelles in the aqueous carrier, are pharmaceutically acceptable when administered by the intended route of administration, and which substantially do not interact with the metal carboxylate complex to pause dissociation from the metal when the composition is stored in the absence of light.
- Suitable surfactants for use in compositions for oral or topical administration include, but are not limited to, the sorbitan fatty acid ester group of surfactants.
- Such surfactants comprise mono-, tri-, or partial esters of fatty acids such as oleic, lauric, palmic and stearic acids, and include sorbitan trioleate (Span 85), sorbitan tnonooleate (Span 80), sorbitan tristearate (Span ⁇ S5), sorbitan monostearate (Span 60), sorbitan mo ⁇ opalmitate (Span 40), and sorbitan motiolaurate (Span 20).
- Other suitable surfactants include me macrogol (polyoxyethylene) esters and ethers. These surfactants include, but are not limited to, the caster oil polyoxyethylene group of surfactants, such a$ Termul 1284 and caster oil ethoxylatc.
- surfactants in this class include the Polyoxyethylene Sorbitan Fatty Acid Esters group of surfactants, including polyoxyethylene (20) sorbitan monolaurate (Tween 20), polyoxyethylene (4) sorbitan monolaurate (Tween 21), and polyoxyethyleae (20) sorbitan monooleate (Tween 80).
- surfactants that may be used include the block copolymers based on ethylene oxide and propylene oxide such Poloxamer 124 (Pluronic IAA NF), P ⁇ l ⁇ xamer 188 (Phironic F68 NF), Poloxamer 331(Pluronic LlOl NF), and Poloxamer 407 (Plirf ⁇ nic Fl 27 NF).
- Suitable surfactants also include the polyethylene glycol fatty acid esters (PEG esters) group of surfactants.
- Such surfactants comprise mono-, tri-, or partial esters of fatty acids such as oleic, lauric, palmic, oleic, and stearic acids, including but not limited to PEG 200 monolaurate, PEC 300 dilaurate, ethylene glycol distearate, PEG 300 raonooleate, PEG 400 monooleate, PEG 350 monostearate, PEG 300 monostearate, PEG 400 monostearate, PEG 600 monostearate, PEG 1000 monostearate, PEG 1800 monostearate, PEG 6500 tnonostearate, PEG 400 mono-iso stearate, PEG 600 mono-iso-stearate, PEG 200 dilaurate, PEG 600 distearate, PEG 6000 distearate, PEG 200 distearate, PEG 300 distearate, and PEG 400 distearate.
- PEG 200 monolaurate PEC 300 dilaurate, ethylene glycol di
- compositions have more than 80%, preferably more than 90%, and mote preferably more than 95%, of the total amount of the carboxylate, or hydroxamate, hydroximate, ester, or amide derivative having anti-inflammatory activity present in the composition as part of a metal complex.
- a metal complex Preferably, also less than 10% of the carboxylate, or hydroxamate, hydroximate, ester or amide derivative complexed with the metal dissociates from the metal when the composition i$ stored for 12 months in the absence of light at room temperature (18 0 C to 25 0 C).
- the amount of the carboxylate, or hydoxamate, hydroximate, ester or amide remaining bound to the metal complex can be readily determined by a person skilled in the art using known methods $uch a$ EPR spectroscopy for complexes that give EPR signals or using more specialized experiments involving X-ray absorption spectroscopy for all complexes (e.g., XAFS Studies of Anti-inflammatory Dinuclear and Mononuclear Zn(II) Complexes of Indomethacin. Zhou, Q.; Hambley, T. W.; Kennedy, B. J.; Lay, P. A.
- the compositions preferably do not comprise, or are substantially free of, peptides, carb ⁇ xylate donors, reductant$ and thiolate groups, apart from those in the derivatives of the NSAID utilised.
- the composition is also not strongly acidic or basic a$ strong acids and bases can cause metal carboxylate complexes to dissociate.
- the metal-NSATD complex can be dissolved in the composition or can be present in the composition as a solid.
- the solid complex can be in the form of a crystal containing solvents of crystallisation and/or waters of crystallisation. When the complex is charged, the complex will be associated with a counter ion.
- a "pharmaceutically acceptable carrier” is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the complex to a human or animal.
- the carrier can be liquid or solid and is selected with the intended manner of administration in mind, The carriei 1 i$ ''pharmaceutically acceptable” in the sense of being not biologically or otherwise undesirable, i.e., the carrier maybe administered to a buman or animal along with the complex without causing any or a substantial adverse reaction ,
- the carrier can be a solvent or dispersion medium containing one or more of physiological saline, ethanol, polyol (e.g. glycerol, propylene glycol, liquid polyethylene glycol and the like), vegetable oils and mixtures thereof.
- composition for use in the method of the invention can be suitable for oral, rectal, nasal, topical (including buccal and sublingual), ophthalmological, vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration, or for administration respiratoraly, intratrachaely, nasopharanyngealy, intraoccularly, i ⁇ trathecally, intranasally. by inhalation, infusion, or via IV group patch and by implant.
- the metal-NSAID complexes can also be delivered into cavities such as for example the pleural or peritoneal cavity.
- a pharmaceutical composition as described herein can also conveniently be presented in unit dosage form and may be prepared by methods well known in the art of pharmacy.
- Such methods include the step of bringing into association the complex with the carrier.
- the carrier comprises two or more ingredients.
- the composition is prepared by uniformly and intimately bringing into association the complex with the carrier, and then, if necessary, shaping the product.
- the complex and the one or more components making up the carrier may be mixed in any order. However, it is preferred that the components are mixed in a manner that minimises the amount of the complex that dissociates during the preparation of the composition.
- a composition for oral administration can be in the form of a viscous paste, an ingestible tablet, a capsule, a chewable composition, or any other form suitable for oral administration.
- the composition can be encapsulated in a hard or soft capsule (e.g. gelatine) by techniques known in the art.
- the metal complex can be provided in the form of buccal tablets, troches, elixirs, suspensions or syrups.
- a composition for oral use can for instance, also comprise one or more agents selected from the group of sweetening agents such as sucrose, lactose or saccharin, disintegrating agents such as corn starch, potato starch or alginic acid, lubricants such as magnesium stearate, flavouring agents, colouring agents and preserving agents e.g. such as s ⁇ rbic acid, in order to produce pharmaceutically elegant and palatable preparations.
- sweetening agents such as sucrose, lactose or saccharin
- disintegrating agents such as corn starch, potato starch or alginic acid
- lubricants such as magnesium stearate
- flavouring agents such as s ⁇ rbic acid
- preserving agents e.g. such as s ⁇ rbic acid
- a chewable composition can, for example, comprise the complex, one or more flavours, a base formulation, one or more preservatives, one or more pH modifiers, one or more desiccants and one or more fillers.
- the base may comprise pre-gel starch, gelatine, flour and water.
- the composition may also comprise other components including phosphoric acid, salt, sugar, sorbitol and/or glycerol, sorbic acid and/or potassium sorbate, benzoic acid, propionic acid and maltodextrin,
- a chewable composition for an animal such as a dog for example, may comprise the complex, meat emulsion, an acidulate (e.g.
- a composition for topical application may comprise the complex in a conventional oil-uvwater emulsion, water-in-oil emulsion, or water-immiscible pharmaceutical carrier suitable for topical application.
- Such carriers include for example, laciilubc, cctomacrogol cream BiP, wool fat ointment BP or emulsifying ointment BP.
- Such carriers are typically in the form of an emulsion or are immiscible with water. Topical formulations could, for instance be used in patches or other $low release vehicles.
- composition for topical application to skin is a composition comprising 0.5-2% w/w of the complex in an emulsifying cream with chlorocresol (4- chloro-3-methylphenol) as a preservative, the emulsifying cream comprising:
- compositions for parenteral administration include compositions in the form of sterile aqueous or non-aqueous suspensions and emulsions.
- the composition can also include one or more pharmaceutically active components in addition to the complex that have anti-inflammatory or other therapeutic activity.
- active components include conventionally used anti -inflammatory drugs.
- a metal complex will constitute about 0.025% to about 20% by weight of the composition, preferably about 0.025% to about 20% by weight of the composition, more preferably about 0.1% to about 20% by weight of the composition and most preferably, the complex constitutes about 0.1 % to about 10% by weight of the composition.
- a composition embodied by the invention may comprise the metal complex in an amount of about J % by weight of the composition or less.
- Suitable pharmaceutically acceptable carriers and formulations useful in the present invention may for instance be found in handbooks and texts well known to the skilled addressee, such as "Remington: The Science and Practice of Pharmacy (Mack Publishing Co., 1995)” and subsequent update versions thereof, the contents of which is incorporated herein in it$ entirety by reference.
- the mammalian subject can be a human or an animal.
- the animal can, for example, be a companion animal such as a dog or cat, or a domestic animal such as a horse, pony, donkey, mule,- camel, llama, alpaca, pig, cow or sheep, or a zoo animal.
- Suitable animals include members of the Orders Primates, Rodentia, Lagomorpha,
- Cetacea, Carnivora, Perissodactyla and Artiodactyla Typically, the subject will be a primate and more usually, a human being.
- a number of embodiments of the present invention will now be described below by reference to the following non-limiting examples,
- Metal complexes useful in one or more embodiments of methods of the invention were prepared as follows.
- Cu(Il) acetate monohydrate (0.028 g, 0.140 mmol) in water (0.75 niL) was added drop wise to indometnacin (0,1 g, 0.28 mmol) dissolved in ethanol (1.75 mL) at room temperature. Warming the eihanol mildly ( ⁇ 40°C) helped solubilise the 5 indomethaoin before adding the Cu(II) acetate solution.
- On addition of the Cu(II) acetate mo ⁇ ohydrate in water bright green Culndo/aqua complex precipitated out of solution immediately. This precipitate was filtered, washed with water and dried.
- Ketorolac tris salt (0.452 g, 1.20 mmol) was dissolved ia water (5 mL).
- VOSO 4 -SH 2 O 50.6 mg, 0.200 mmol
- IndpHAHj 149 mg, 0.400 mmol
- methanol MeOH, HPLC grade, 5.0 mL
- the solution immediately turned dark-red.
- This solution was added to ice-cold H 2 O (Milli-Q grade, 50 mL), which led to the formation of a fine brown precipitate.
- the precipitate was isolated by centrifugation (5 min at 4000 g) and dissolved in a minimal volume of MeOH (-20 mL).
- the resultant solution (which was slightly cloudy) was filtered through a small-pore (No. 4) glass filter under vacuum.
- An acidic aqueous solution of Ga(IIT) (0.64 M) was prepared by partial dissolution of a piece of metallic Ga (99.99%, Fluka) in aqueous HCl ( ⁇ 5 M, ultra-pure, Merck), and the amount of dissolved Ga was determined by the mass difference. A portion of this solution (5,0 mM) was evaporated to dryness at 100 0 C, and the residue was dried under vacuum overnight and dissolved in anhydrous MeOH (5.0 mL), giving a solution OfGaCl 3 (0.64 M) in MeOH.
- the Ga content in the complex determined spcctrophotometrically with 4-(2-pyridylazo)resorcine (PAR) after digestion of the complex with concentrated HNOj, was 8.0 and 8.7% (for two parallel samples).
- the data the formation of a bis-ligated Ga(III) hydroxamato complex, [Ga(LH) 2 (OHa) 2 J +
- Rat paw oedema studies on this complex using the methodology described in Example 2 gave 30% reduction in inflammation and, remarkably, no gastric ulceration when dosed at 10 ⁇ g/kg Indo molar equivalent and dissolved into an MCT paste.
- HBTU ⁇ 9-(Benzotriazol-l - yl)-N, ⁇ W'.N-tetramethyluronium hexafluorophosphate
- ligands can be prepared by the following reaction schemes and can coordinate to metal i ⁇ n$ via the di ⁇ l functions.
- Complexes such as the Co(III) complex described in Example 1.1.3 offer the potential of systemic delivery of even higher concentrations of NSAIDs through oral, injectable, and topical delivery and incorporation into slow release patches, A$ demonstrated by this example, the complex exhibits significant antiinflammatory.
- Rats were dosed with indomethaci ⁇ and [Cu 2 (Indo) 4 (DMF)i] for 28 days.
- Acute gastrointestinal toxicity was measured using gastrointestinal permeability markers, gastrointestinal ulceration and bleeding, and measurement of an acute phase protein haptoglobin.
- the effects of acute and chronic administration of indomcthacin. and [Cu 2 (Indo) 4 (DMF) 2 ] on urinary electrolyte concentrations were examined.
- CMQ carboxymethylcellulose
- HEPES penicillin-streptomycin
- sodium bicarbonate sucrose McCoy's 5A medium and methylene blue
- [Cu 2 (LIdO) 4 (DMF) 2 was used as supplied by Biochemical and Veterinary Research Limited (Mittagong, MSW, Australia) and Vetafarm (Wagga Wagga, Australia). Sprague-Dawley rats weighing 200-250 g were used throughout this study.
- Animals were housed in polypropylene cages and allowed free access to standard laboratory rat chow (Purina Rat Chow, Ralston Purina, St Louis MO, USA) aad tap water. Animals were housed in an animal care facility at ambient temperature and S humidity with a 12-h light-dark cycle. The experimental animal protocols were approved by animal ethics committees at The University .of Sydney, Australia and Washington State University, USA.
- the rats received either oral indomethacin at doses of 10 mg/kg or [Cu 2 (Indo) 4 (DMF) 2 ] at do$es of ⁇ 3.3 mg/kg via gavage.
- Plasma was obtained by cardiac puncture using a 23 gauge (G) needle, attached to a 10 mL syringe, under halothane anaesthesia.
- Haptoglobin concentration (milligrams per millilitre) was measured using a 5 commercially available kit Dade Behring (Mannheim, Germany) by radial immunodiffusion using 5- ⁇ L $am ⁇ les in each well.
- Normal range values are a diffusion zone of approximately 6 mm of diameter (1.22 g/L).
- the diameter of the precipitin zone is directly proportional to the concentration of the relevant protein in the sample (Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in 0 the rat when dosed orally for one month; comparison with tiaprofenic acid and etodolac.
- the rats received either oral indomethacin at doses of 10 mg/kg or [Cuj(Indo)4(DMF)j] at doses of 133 mg/kg via gavage. Since [Cu 2 (InUo) 1 I(DMF) 2 J consists of a copper moiety and an indomethacin moiety, a higher dose of this compound was given so that an equivalent amount of the NSAID moiety was being delivered as in the i ⁇ domethacin-treated rats.
- the compounds 0 were suspended in 2% carboxymethylcellulose.
- Rats were deprived of food, but not water, for 18 h and were administered indomethacin, [Cu2(-ndo)4(DMF)2] or vehicle. Animals were anesthetized with halothane 3 h after the dose and the stomach was excised and opened by an incision along the greater curvature for assessment of macroscopic visible damage by an observer unaware of the treatment the rats had received using a method described previously (Aspirin causes rapid up-regulation of cydooxygenase-2 expression in the stomach of rats. Davies, N.M.; Sharkey, K.A.; Asfaha, S.; Macnaughton, W.K.; Wallace, J.L. Aliment. Pharmacol Ther. 1997, 11, 1101-18).
- the length of lesions was measured (in millimetres) using digital callipers and then the lengths of all lesions observed in each stomach were added together ($ee Figure 2). After scoring, the gastric tissue was fixed in neutral buffered formalin and processed by routine techniques prior to embedding in paraffin, sectioning and $taioing with hematoxylin and eosin.
- Sucrose permeability changes were measured using a previously reported method (Sucrose urinary excretion in the rat using a simple assay; a model of gastroduodcnal permeability. Davies, N.M.; Corrigan ⁇ B.W.; Ja ⁇ iali, F. Pkarnt. Res. 1995, 12, 1733-6).
- Rats ( « 4 for each treatment) were deprived of food, but not water, for 18 h and fasted overnight.
- the rats received either oral ind ⁇ methacin at doses of 10 mg/kg or [Cu 2 (lndo) 4 (DMFh] at doses of 13,3 mg/kg via gavage.
- an aqueous solution 0.5 niL
- Urine was collected 0-24 h following the administration of the sucrose solution.
- Relative permeability was determined by calculating the sucrose present in each urine sample as a percent of the administered dose (sec Figure 3).
- Rats ( « 4 for each treatment) received either oral ind ⁇ methacin at doses of 10 mg/kg or [Cua(Indo)4(DMF) 2 ] at doses of 13.3 mg/kg via gavage.
- oral ind ⁇ methacin at doses of 10 mg/kg or [Cua(Indo)4(DMF) 2 ] at doses of 13.3 mg/kg via gavage.
- the animals were sacrificed 24 h after dosing and the intestines removed. A vertical mid-line abdominal incision was made, and the entire length of the small intestine was isolated, excised, and examined extending 10 cm distal to the ligament of Treitz to the ileocecal junction.
- a 26 G needle attached to 5-mL syringe was used to flush the intestine in order to avoid distension.
- Intestinal ulceration was determined by measuring the length of lesions in millimetres using digital callipers and the lengths of all lesions observed in each intestine summed (NO-naproxen vs. naproxen: ulcerogenic, analgesic and antiinflammatory effects. Davies, N.M.; Roseth, A.G.; Appleyard, C.B.; etal Aliment, Pharmacol. Ther. 1997, //, 69-79) (see Figure 5).
- tissue sections were obtained from damaged areas for histology. Tissue sections were embedded in plastic using a commercially available kit (JB-4 embedding kit, Polysciences. Inc. Wa ⁇ ington, PA). Embedded tissues were cut to thin sections (1-1.5 ⁇ rn) and the sections were stained with Lee's methylene blue- basic fuchsin for 30 seconds. Sections were then examined by light microscopy.
- Rats ( « 4 for each treatment) received either oral indomethacin at doses of 10 mg/kg or [Cu2(Indo)i)(DMF) 2 ] at doses of 13.3 mg/kg via gavage.
- the animals were sacrificed 24 h after dosing and the intestines were removed. A vertical mid-line abdominal incision was made, and the entire length of the small intestine was isolated, excised, and examined extending 10 cm distal to the ligament of Treitz to the ileocecal junction.
- Intestinal tissue samples (-1 g) were obtained from the distal ileum, placed into Petri dishes containing sterile phosphate-buffered saline (pH 7.4), and weighed.
- the tissues were homogenized and plated onto MacConk ⁇ y agar No. 2 (Oxoid, NSW, Australia) and incubated at 37°C for 24 h under aerobic conditions. Plates containing between 20 and 200 colony-forming units (CFU) were analysed to determine total enteric bacterial numbers per gram of tissue (Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Reuter, B.K.; Davies, N.M.; Wallace, LL. Gastroenterology 1997, 112, 109-17) (see Figure 8). 23.6 Mitochondrial DNA
- Quantitative polymerase chain reaction (QPCR) was used as previously described (Chemotherapy B induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and eyclooxygenase-2. Yanez, J.A.; Teng, X. W.; Roupe, K.A.; Fariss, M, W,; Davies, N.M. J, Pharm, Pharm. Sd 2003, 6, 308-314).
- DNA was isolated from afflicted intestinal tissue using Qiagen® genomic tip and genomic DNA buffer $et kit for mammalian DNA extractions (Valencia, CA 1 USA).
- 0 DNA quantitation utilized the PicoGreen® dsDNA Quantitation Kit (Molecular Probes, Eugene, OR, USA), Picogreen® wa$ u$ed to quantify dsDNA fragment.
- QPCR involved the use of GeneAmp XL PCR kit (Applied Biosystems, Branchburg, NJ, USA) and dNTP$ (Pharmacia, Peapack, NJ, USA). Primers were based on sequences already optimized by Van Houten (Analysis of gene-specific DNA damage and repair using 5 quantitative polymerase chain reaction.
- Rat$ 10 rag/kg or [Oi 2 (Indo) 4 (DMF) 2 ] at doses of 13.3 mg/kg via gavage.
- Rat$ were housed in special metabolic cages where urine and faeces were collected separately 0-24 h after administration.
- the colorinietric assay kit was obtained from Boehringer Mannheim. The instructions and procedures were followed as documented by the manufacturer. 0 S-Cresolsulfonphthalenyl-N-acetyl- ⁇ -D-glucosaminide, sodium salt was hyd ⁇ oly$ed by
- a composition comprising the [Cu2(Indo) ⁇ (OHz)2] complex in MCT oil was prepared for subcutaneous and intramuscular injections.
- the competition comprised the following ingredients:
- Tetraglycol is the solvent; Delios V MCT oil is a medium chain triglyceride oil.
- the composition was prepared as follows:
- the composition was a single-phase dark green oil immiscible in water.
- the 25 composition contained >95% of Indo in the composition as part of the dimer
- Sprague-Dawley rats (weighing 200-250 g) used for these studies were supplied by the laboratory animal services at The University of Sydney. Animals were housed in polypropylene cages and allowed free acce$$ to standard laboratory rat chow (ftirina Rat Chow, Ralston Purina, St Louis MO) and tap water. Animals were housed in the animal care facility of the Faculty of Pharmacy at ambient temperature and humidity with a 12-h light-dark cycle. The experimental animal protocols were approved by the Animal Ethics Committee of the University of Sydney.
- the control cohort was injected with equivalent volumes of neat MCT, Subcutaneous injections were made in the lower dorsal surface and intramuscular injections were made in the right hind thigh muscle. Inflammation was induced 1 h after dosing by injection of the formulation by an injection of carrageenan (0,1 ml, 1% w/v in isotonic saline) into the plantar region of the hind paw.
- Paw volume was measured prior to dosing and at 3 h after carrageenan injection by immersing the left hind paw (to the lateral malleus) into a vessel filled with water and measuring the volume of water displaced as decribed in International Patent
- composition containing [Cu2(I ⁇ d ⁇ )4 ⁇ OH 2 )2] in MCT oil has a similar efficacy and safety profile in r»t$ a$ those observed following subcutaneous injections, although the efficacy for treatment of inflammation i$ higher in the plateau region of the dose-response curve,
- compositions containing and IndoH have similar efficacy
- the composition containing [Cu2(I ⁇ do) 4 ( ⁇ H2)2] in MCT oil resulted in less GI toxicity.
- composition containing the complex in MCT oil Both subcutaneous and intramuscular administration of the composition containing the complex in MCT oil have considerable efficacy, with the latter mode of administration being more efficacious. If the composition was delivered as a physical mixture of a Cu salt and IndoH or the composition caused the complex to dissociate with the release of free Indo, then toxicity effects similar to those of ⁇ idoH are expected,
- compositions The composition containing the metal complexes in medium chain triglyceride
- MCT organogel paste and/or an aqueous 2% w/w CMC solution were freshly prepared for each experiment.
- the organogel paste is described in PCT International Patent Application No. PCT/AU2005/000442.
- Sprague-Dawley rats (weighing 200-250 g) used for these studies were supplied by the laboratory animal services at The University of Sydney, Sydney Australia, Animals were housed in polypropylene cages and allowed free access to standard laboratory rat chow (Purina Rat Chow, Ralston Purina, St Louis MO) and tap water. Animals were housed in the animal care facility of the Faculty of Pharmacy at ambient temperature and humidity with a 12-h light-dark cycle. The experimental animal protocols were approved by the Animal Ethics Committee of the University of Sydney.
- Inflammation was induced (1 h after dosing by gavage with an injection of csrrageenan (0,1 mL, 1 % w/v in isotonic saline) into the plantar region of the hind paw.
- Paw volume was measured prior to dosing and at 3 h after carrageenan injection by immersing the left hind paw (to the lateral malleus) into a vessel filled with water and measuring the volume of water displaced as decribed in International Patent Application No. PCT/AU2005/000442 filed 30 March 2005..
- 24 h-fasted animals were euthanased and the stomach was excised and opened by incision along the greater curvature. The stomach was rinsed and examined to determine the extent of macroscopic gastric toxicity, which is reported as the summation of the area of macroscopic ulcerations (mm 2 ).
- DP placebo groups
- drug was administered as a single gavage dose (4 mg/kg of oxametaci ⁇ equivalent, delivered as the vanadium complex in an MCT organogel) between 7 and 9 am in the morning.
- tail vein blood was obtained immediately before administration and at 2, 4, 6, 8 and 18 hr following administration of the vanadium complex. Blood sugar level was measured by glucometer (Ames).
- the BSL of diabetic animals treated with either drug (black circles) or placebo (open circles) are shown in Fig. 11.
- treatment of diabetic animals with the vanadium complex induced a 6-10-mmoH decrease in blood glucose level when compared with the placebo treated group. This decrease was maintained for a farther 6 hr and had returned to baseline levels by 24 hr.
- Treatment of non-diabetic control animals had no blood sugar lowering effect over a similar time course (data not shown).
- These data indicate that the drug has insulin-like action in that it can lower blood glucose levels in diabetic animals at much lower concentrations of vanadium than is normally administered to observe such effects.
- the results also illustrate the potential role for the drug in simultaneously treating diabetes and inflammatory conditions in the one dose (cither alone or in combination therapy with drug(s) conventionally used for the treatment of diabetes) for humans and animals suffering from this condition.
- V hydroximato complexes previously used for lowering BSL have comparable activity to BMOV ("Synthesis of vanadium(lV,V) hydroxamic acid complexes and in vivo assessment of their insulin-like activity".
- Cr(IIl) complexes described herein such as Cr(IIIj-IndoHA, as Cr(III) complexes (non-NSAlD complexes) are known anti-diabetic agents and are comsumed as dietary supplements to improve glucose metabolism.
- Synergistic effects as observed for the vanadium complex would render the dose of the Cr(IIl) ion below the normal dietary intake of Cr such that no essentially no toxic side-effects would be expected (Chromium in Biology: Nutritional. Aspects and Toxicology. Levins, A.; Codd, R.; Dillon, C. T.; Lay, P, A.
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des méthodes de prophylaxie ou de traitement d'états diabétiques ou prédiabétiques. Les méthodes consistent à administrer une dose thérapeutique d'un complexe de métal et d'un carboxylate, ou un dérivé d'un carboxylate, ayant une activité anti-inflammatoire.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006901583 | 2006-03-28 | ||
AU2006901583A AU2006901583A0 (en) | 2006-03-28 | Method for prophylaxis or treatment | |
US83029006P | 2006-07-11 | 2006-07-11 | |
US60/830,290 | 2006-07-11 | ||
AU2006905170A AU2006905170A0 (en) | 2006-09-19 | Metal complexes having anti-inflammatory activity | |
AU2006905170 | 2006-09-19 | ||
AU2006905267A AU2006905267A0 (en) | 2006-09-22 | Metal complexes having anti-inflammatory activity | |
AU2006905265A AU2006905265A0 (en) | 2006-09-22 | Metal complexes having anti-inflammatory activity II | |
AU2006905265 | 2006-09-22 | ||
AU2006905267 | 2006-09-22 | ||
AU2006905378A AU2006905378A0 (en) | 2006-09-28 | Metal complexes having anti-inflammatory activity II | |
AU2006905377A AU2006905377A0 (en) | 2006-09-28 | Metal complexes having anti-inflammatory activity | |
AU2006905377 | 2006-09-28 | ||
AU2006905378 | 2006-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007109845A1 true WO2007109845A1 (fr) | 2007-10-04 |
Family
ID=38540716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2007/000381 WO2007109845A1 (fr) | 2006-03-28 | 2007-03-28 | Prophylaxie ou traitement du diabète |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007109845A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062221A1 (fr) * | 2008-11-27 | 2010-06-03 | Алла Xem, Ллс | Acides 2-(5-hydroxy-2-méthyl-1n-indole-3-il) acétiques substitués, leurs éthers et leur utilisation pour traiter des maladies virales |
CN110066288A (zh) * | 2018-01-24 | 2019-07-30 | 南京大学 | 一种具有抑制脲酶活性的萘普生铜配合物及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024180A2 (fr) * | 2000-09-21 | 2002-03-28 | Nutrition 21, Inc. | Procedes et compositions pour le traitement du diabete, la reduction des graisses corporelles, l'amelioration de la sensibilite a l'insuline, la reduction de l'hyperglycemie et la reduction de l'hypercholesterolemie, a l'aide de complexes de chrome, d'acides gras conjugues et/ou d'alcools gras conjugues |
WO2002036127A2 (fr) * | 2000-10-31 | 2002-05-10 | Nutrition 21, Inc. | Methodes et compositions avec complexes au chrome pour personnes atteintes de polykystose ovarienne |
WO2002036202A2 (fr) * | 2000-11-02 | 2002-05-10 | Nutrition 21, Inc. | Procedes et compositions permettant d'ameliorer la sensibilite insulinique, de reduire l'hyperglycemie, et de reduire l'hypercholesterolemie a l'aide de complexes de chrome et d'acide alphalipoique |
WO2006099677A1 (fr) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Complexes metalliques |
WO2006099684A1 (fr) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Complexes de cuivre |
-
2007
- 2007-03-28 WO PCT/AU2007/000381 patent/WO2007109845A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002024180A2 (fr) * | 2000-09-21 | 2002-03-28 | Nutrition 21, Inc. | Procedes et compositions pour le traitement du diabete, la reduction des graisses corporelles, l'amelioration de la sensibilite a l'insuline, la reduction de l'hyperglycemie et la reduction de l'hypercholesterolemie, a l'aide de complexes de chrome, d'acides gras conjugues et/ou d'alcools gras conjugues |
WO2002036127A2 (fr) * | 2000-10-31 | 2002-05-10 | Nutrition 21, Inc. | Methodes et compositions avec complexes au chrome pour personnes atteintes de polykystose ovarienne |
WO2002036202A2 (fr) * | 2000-11-02 | 2002-05-10 | Nutrition 21, Inc. | Procedes et compositions permettant d'ameliorer la sensibilite insulinique, de reduire l'hyperglycemie, et de reduire l'hypercholesterolemie a l'aide de complexes de chrome et d'acide alphalipoique |
WO2006099677A1 (fr) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Complexes metalliques |
WO2006099684A1 (fr) * | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Complexes de cuivre |
Non-Patent Citations (1)
Title |
---|
SORENSON J.R., PROGRESS IN MEDICINAL CHEMISTRY, vol. 26, 1989, pages 437 - 568 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062221A1 (fr) * | 2008-11-27 | 2010-06-03 | Алла Xem, Ллс | Acides 2-(5-hydroxy-2-méthyl-1n-indole-3-il) acétiques substitués, leurs éthers et leur utilisation pour traiter des maladies virales |
CN110066288A (zh) * | 2018-01-24 | 2019-07-30 | 南京大学 | 一种具有抑制脲酶活性的萘普生铜配合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5563452B2 (ja) | 一酸化炭素による胃潰瘍の予防 | |
WO2008100418A1 (fr) | Complexes de zinc d'acides aminés naturels pour le traitement de toxicités provoquées par un cuivre élevé | |
JP7074761B2 (ja) | 治療用デンドリマー | |
JP6075903B2 (ja) | Pfkfb2阻害剤および抗癌治療法としての使用方法 | |
ES2954451T3 (es) | Composiciones y usos de derivados de amidina | |
WO2007110755A1 (fr) | Prophylaxie ou traitement d'une inflammation cardio-vasculaire | |
CN102014870A (zh) | 活性的一氧化氮供体及其制备和应用的方法 | |
JP5820080B2 (ja) | 三環系PI3K及び/又はmTOR抑制剤 | |
EP3386967A1 (fr) | Combinaisons pour le traitement de calculs rénaux | |
WO2006099685A1 (fr) | Methode de prevention ou de traitement de carcinomes | |
BR112019000290B1 (pt) | Prófármacos de fósforo dos estimuladores da sgc | |
WO2007026240A1 (fr) | Écran solaire et compositions cosmétiques pour la prophylaxie ou pour le traitement des cancers de la peau | |
WO2007109845A1 (fr) | Prophylaxie ou traitement du diabète | |
WO2006099677A1 (fr) | Complexes metalliques | |
AU2017235350A1 (en) | Combination therapy for proliferative diseases | |
WO2007110745A1 (fr) | Polythérapie destinée à traiter le cancer | |
US20080039522A1 (en) | Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity | |
WO2007109843A1 (fr) | Complexes métalliques ayant une activité anti-inflammatoire | |
WO2011100983A1 (fr) | Caséine en tant que nouveau système de véhicule de médicament de curcumine | |
US20060264408A1 (en) | Sod minic multifunctional compounds for treating inflammatory bowel disease | |
WO2006099684A1 (fr) | Complexes de cuivre | |
TWI222358B (en) | Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith | |
EP1185540B1 (fr) | Complexes dimeres de ruthenium pouvant etre utilises en tant qu'agents antineoplasiques et antimetastasiques | |
WO2018015493A1 (fr) | Complexes métalliques ayant des applications thérapeutiques | |
KR20100001602A (ko) | 가용화된 니플루믹산을 함유하는 약학 제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07718628 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 23.01.2009. |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07718628 Country of ref document: EP Kind code of ref document: A1 |